EP1734941A2 - Neural tourniquet - Google Patents
Neural tourniquetInfo
- Publication number
- EP1734941A2 EP1734941A2 EP05755668A EP05755668A EP1734941A2 EP 1734941 A2 EP1734941 A2 EP 1734941A2 EP 05755668 A EP05755668 A EP 05755668A EP 05755668 A EP05755668 A EP 05755668A EP 1734941 A2 EP1734941 A2 EP 1734941A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- agonist
- subject
- vagus nerve
- cholinergic
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- BACKGROUND OF THE INVENTION Excessive bleeding can occur as a consequence of injury, surgery, inherited bleeding disorders, or bleeding disorders which are developed during certain illnesses (such as vitamin K deficiency, severe liver damage) or treatments (such as the use of anticoagulant drugs or prolonged use of antibiotics).
- Some of the risks associated with bleeding disorders include scarring of the joints or joint disease, vision loss from bleeding into the eye, chronic anemia from blood loss, and death which may occur with large amounts of blood loss or bleeding in critical areas such as the brain.
- Bleeding disorders result from an inability of the blood to clot. This inability is most commonly caused by a deficiency of blood coagulation factors. Other less common causes include a deficiency in blood platelets or a disorder in platelet function.
- Hemophilia A is one of the most frequently occurring inherited coagulation disorders. Patients with hemophilia A are prone to frequent hemorrhages as a result of a deficiency in Factor NHL Common treatments for people with bleeding disorders such as hemophilia A, include factor replacement therapy. This is the injection into the bloodstream of Factor N-ffl concentrates to prevent or control bleeding. Factor replacement therapy can also be used to reduce postoperative bleeding in high risk surgical procedures. The main disadvantage of factor replacement therapy, however, is the increased risk of exposure to blood-borne infections such as hepatitis due to infusions of blood products.
- bleed time can be reduced in a subject by activation of the cholinergic anti-inflammatory pathway in said subject.
- the cholinergic anti-inflammatory pathway can be activated by direct stimulation of the vagus nerve in the subject. For example, it has been shown by the inventor that electrical stimulation of the vagus nerve leads to decreased bleed time in laboratory mice (see Examples 1 and 2).
- the cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of a cholinergic agonist to the subject. For example, it has been further shown by the inventor that administration of nicotine to laboratory mice, decreases bleed time in the mice (see Example 3).
- One embodiment of the present invention is a method of reducing bleed time in a subject by activating the cholinergic anti-inflammatory pathway.
- the cholinergic anti-inflammatory pathway can be activated by stimulating the vagus nerve in the subject.
- the vagus nerve can be indirectly stimulated by administering an effective amount of muscarinic agonist to the subject.
- muscarinic agonists include: muscarine, McN-A-343, MT-3 and CNI-1493.
- the cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist to the subject.
- a suitable cholinergic agonist is nicotine.
- the cholinergic agonist is selective for an ⁇ -7 nicotinic receptor;
- suitable ⁇ -7 selective nicotinic agonists include: GTS-21, 3-(4-hydroxy-2-methoxybenzylidene) anabaseine, choline, cocaine methiodide, trans-3-cinnamylidene anabaseine, trans-3-(2-methoxy- cinnamylidene)anabaseine, or trans-3-(4-methoxycinnamylidene)anabaseine.
- the cholinergic anti-inflammatory pathway can also be activated by electrical stimulation of the vagus nerve in the subject or mechanical stimulation of the vagus nerve.
- Figure 1 is a graph showing the decrease in bleed time in seconds in laboratory mice, after vagus nerve stimulation at 1 volt for 20 minutes. This result is compared to a longer bleed time in a control group in which the vagus nerve was isolated but not stimulated.
- Figure 2 is a graph showing the decrease in bleed time in seconds in laboratory mice, after vagus nerve stimulation at 1 volt for 30 seconds. This result is compared to a longer bleed time in a control group in which the vagus nerve was isolated but not stimulated.
- Figure 3 is a graph showing the decrease in bleed time in seconds in laboratory mice after administration of nicotine. This result is compared to a longer bleed time in a control group to which a saline solution was administered.
- Figure 4 is a graph showing the decrease in bleed time in seconds in two groups of laboratory mice after tail amputation. The first group was administered
- FIG. 5 is a graph showing the prothrombin time in (PT) seconds in laboratory mice after electrical vagus nerve stimulation (1 V, 2 ms pulse width, 1Hz for 30 seconds).
- Figure 6 is a graph showing the activated partial thromboplastin (APTT) time in seconds in laboratory mice after electrical vagus nerve stimulation (IV, 2 ms pulse width, 1Hz for 30 seconds).
- Figure 7 is a graph showing the activated clotting time (ACT) in seconds in laboratory mice after electrical vagus nerve stimulation (IV, 2 ms pulse width, 1Hz for 30 seconds).
- Figure 8 is a graph showing the decrease in bleed time in seconds in conscious laboratory mice after administration of nicotine. This result is compared to a longer bleed time in a control group to which a saline solution was administered.
- Figure 9 is a graph showing the effect of administration of the alpha-7 antagonist MLA to mice prior to administration of nicotine.
- a subject is preferably a mammal, more preferably a human patient but can also be a companion animal (e.g., dog or cat), a farm animal (e.g., horse, cow, or sheep) or a laboratory animal (e.g., rat, mouse, or guinea pig).
- the cholinergic anti-inflammatory pathway refers to a biochemical pathway in a subject, that is activated by cholinergic agonists and reduces inflammation in the subject.
- the cholinergic anti-inflammatory pathway is described in U.S. Patent Publication No. 2004/0204355 filed December 5, 2003 and
- the vagus nerve includes nerves that branch off from the main vagus nerve, as well as ganglions or postganglionic neurons that are connected to the vagus nerve.
- the effect of vagus nerve stimulation on bleed time is not necessarily limited to that caused by acetylcholine release.
- the scope of the invention also encompasses other mechanisms which are partly or wholly responsible for the reduction of bleed time by vagus nerve stimulation. Nonlimiting examples include the release of serotonin agonists or stimulation of other neurotransmitters.
- the terms 'reduce' or 'reduced' when referring to bleed time in a subject encompass at least a small but measurable reduction in bleed time over non-treated controls.
- the bleed time is reduced by at least 20% over non-treated controls; in more preferred embodiments, the reduction is at least 70%; and in still more preferred embodiments, the reduction is at least 80%.
- activation of the cholinergic anti-inflammatory pathway, and the reduction of bleed time in a subject is achieved by indirect stimulation of the vagus nerve.
- indirect stimulation includes methods which involve secondary processes or agents which stimulate the vagus nerve.
- a secondary agent is a pharmacological vagus nerve stimulator.
- the pharmacological vagus nerve stimulator is an agonist (such as a muscarinic agonist) that activates a muscarinic receptor in the brain.
- a muscarinic agonist is a compound that can bind to and activate a muscarinic receptor to produce a desired physiological effect, here, the reduction of bleed time.
- a muscarinic receptor is a cholinergic receptor which contains a recognition site for a muscarinic agonist (such as muscarine).
- the muscarinic agonist is non-selective and can bind to other receptors in addition to muscarinic receptors, for example, another cholinergic receptor.
- An example of such a muscarinic agonist is acetylcholine.
- the muscarinic agonist binds muscarinic receptors with greater affinity than other cholinergic receptors, for example, nicotinic receptors (for example with at least 10% greater affinity, 20% greater affinity, 50% greater affinity, 75%) greater affinity, 90%) greater affinity, or 95% greater affinity).
- the muscarinic agonist is selective for an Ml, M2, or M4 muscarinic receptor (as disclosed in U.S. Patent No. 6,602,891, U.S. Patent No. 6,528,529, U.S. Patent No. 5,726,179, U.S. Patent No. 5,718,912, U.S. Patent No. 5,618,818, U.S. Patent No.
- an agonist that is selective for an Ml, M2, or M4 receptor is an agonist that binds to an Ml, M2, and/or M4 receptor with greater affinity than it binds to at least one, or at least two, or at least five other muscarinic receptor subtypes (for example, M3 or M5 muscarinic receptors) and/or at least one, or at least two, or at least five other cholinergic receptors, hi a preferred embodiment, the agonist binds with at least 10% greater affinity, 20%> greater affinity, 50% greater affinity, 75%> greater affinity, 90% greater affinity, or 95%> greater affinity than it binds to muscarinic and/or cholinergic receptor subtypes other than Ml, M2, and/or M4 receptors.
- Binding affinities can be determined using receptor binding assays known to one of skill in the art.
- preferred muscarinic agonists useful for these methods include: muscarine, McN-A-343, and MT-3.
- the muscarinic agonist is N,N'-bis (3,5-diacetylphenyl) decanediamide tetrakis (amidmohydrazone) tetrahydrochloride (CM- 1493), w-hich has the following structural formula:
- the muscarinic agonist is a CM- 1493 compound.
- Z is -NH(CO)NH-, -(C 6 H 4 )-, -(C 5 ?Ml 3 )-, or - A-(CH 2 ) n -A-, n is 2- 10, which is unsubstituted, mono- or di-C-methyl substituted, or a mono or di- unsaturated derivative thereof;
- A independently, is -NH(CO)-, -NH(CO)NH-, -NH-, or -O-, and pharmaceutically acceptable salts thereof.
- a preferred embodiment includes those compounds where A is a single functionality. Also included are compounds having the structural formula I when X x and X 2 are H
- a CM- 1493 compound also includes an aromatic guanylhydrazone compound having the structural formula II:
- compounds of structural formula II include the genus wherein, when any of X' l9 X' 2 , and X' 3 are other than H, then the corresponding substituent of the group consisting of X X 2 , and X 3 is meta or para to X'êt X' 2 , and X' 3 , respectively; the genus when m l5 m 2 , and m 3 are 0 and A is -NH(CO)-; and the genus when m l5 m 2 , and m 3 are 2-6, A is
- CM- 1493 compounds and methods for making such compounds are described in U.S. Patent No. 5,854,289 (the contents of which are incorporated herein by reference).
- the cholinergic anti-inflammatory pathway is activated by administering an effective amount of cholinergic agonist to a subject, thus reducing bleed time in said subject.
- a cholinergic agonist is a compound that binds to and activates a cholinergic receptor producing a desired physiological effect, here, the reduction of bleed time in a subject.
- cholinergic agonists suitable for use in the disclosed invention include: acetylcholine, nicotine, muscarine, carbachol, galantamine, arecoline, cevimeline, and levamisole.
- the cholinergic agonist is acetylcholine, nicotine, or muscarine.
- the cholinergic agonist is an ⁇ 7 selective nicotinic cholinergic agonist.
- an ⁇ 7 selective nicotinic cholinergic agonist is a compound that selectively binds to and activates an ⁇ 7 nicotinic cholinergic receptor in a subject.
- Nicotinic cholinergic receptors are a family of ligand-gated, peiitameric ion channels. In humans, 16 different subunits ( ⁇ l-7, ⁇ x9- 10, ⁇ l-4, ⁇ , e, and ⁇ ) have been identified that form a large number of homo- and hetero-pentameric receptors with distinct structural and pharmacological properties (Lindstrom, J.M., Nicotinic Acetylcholine Receptors.
- a cholinergic agonist is selective for an ⁇ 7 nicotinic cholinergic receptor if that agonist activates an ⁇ 7 nicotinic cholinergic receptor to a greater extent than the agonist activates at least one other nicotinic receptor. It is preferred that the ⁇ 7 selective nicotinic agonist activates the ⁇ 7 nicotinic receptor at least two-fold, at least five-fold, at least ten-fold, and most preferably at least fifty- fold more than at least one other nicotinic receptor (and preferably at least two, three, or five other nicotinic receptors).
- Such an activation difference can be measured by comparing activation of the various receptors by any -known method, for example using an in vitro receptor binding assay, such as those produced by NovaScreen Biosciences Corporation (Hanover MD), or by the methods disclosed in WO 02/44176 ( ⁇ 4 ⁇ 2 tested), U.S. Patent No. 6,407,095 (peripheral nicotinic receptor of the ganglion type), U.S. Patent Application Publication No.
- the ⁇ 7 selective nicotinic agonist is a compound of structural formula HI:
- R is hydrogen or methyl, and n is 0 or 1, and pharmaceutically acceptable salts thereof,
- the ⁇ 7 selective nicotinic agonist is (-)- spiro[l-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one]. Methods of preparation of compounds of structural formula in are described in U.S. Patent No. 5,902,814, the contents of which are incorporated herein by reference in their entirety.
- the 7 selective nicotinic agonist is a compound of structural formula -TV:
- m is 1 or 2; n is 0 or 1; Y is CH, N or NO; X is oxygen or sulfur; W is oxygen, H 2 or F 2 ; A is N or C(R 2 ); G is N or C(R 3 ); D is N or C(R 4 ); with the proviso that no more than one of A, G and D is nitrogen but at least one of Y, A, G, and D is nitrogen or NO; R 1 is hydrogen or to C 4 alkyl, R 2 , R 3 , and R 4 are independently hydrogen, halogen, Cj- alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, aryl, heteroaryl, OH, OC C 4 alkyl, CO ⁇ -CN, -NO 2 , -NR 5 R 6 , -CF 3 ⁇ or -OSO 2 CF 3 , or R 2 and R 3 , or R 3 and R 4 , respectively, may together form another six membered aromatic or hetero
- the ⁇ 7 selective nicotinic agonist is (R)-(-)-5'-phenylspiro[l-aziobicyclo[2.2.2]octane-3,2'(3'H)- furo[2,3-b]pyridine].
- Methods of preparation of compounds of structural formula IV are described in the U.S. Patent No. 6,110,914, the contents of which are incorporated herein by reference in their entirety.
- the ⁇ 7 selective nicotinic agonist is a compound of structural formula V:
- R 1 , R 6 and R 7 are hydrogen or C r C 4 alkyl; alternatively R 1 is hydrogen or C C 4 alkyl, and R 6 and R 7 are absent, hydrogen or C r C 4 alkyl; and R 2 is:
- R 3 , R 4 , and R 5 are hydrogen, Cj- alkyl optionally substituted with N,N- dialkylamino having 1 to 4 carbons in each of the alkyls, C r C 6 alkoxy optionally substituted withN, N-dialkylamino having 1 to 4 carbons in each of the alkyls, carboalkoxy having 1 to 4 carbons in the alkoxy, amino, amido having 1 to 4 carbons in the acyl, cyano, and N,N-dialkylamino having 1 to 4 carbons in each of the alkyls, halo, hydroxyl or nitro.
- the ⁇ 7 selective nicotinic agonist is a compound of structural formula V when R 2 is attached to the 3-position of the tetrahydropyridine ring.
- R 3 which may preferably be attached to the 4- or the 2-position of the phenyl ring, is: amino, hydroxyl, chloro, cyano, dimethylamino, methyl, methoxy, acetylamino, acetoxy, or nitro.
- the ⁇ 7 selective nicotinic agonist is a compound of structural formula V, when R 3 is hydroxyl, and R 1 , R 4 , and R 5 are hydrogen
- the ⁇ 7 selective nicotimc agonist is a compound of structural formula V, when R 3 is acetylamino and R 1 , R 4 , and R 5 are hydrogen.
- the ⁇ 7 selective nicotinic agonist is a compound of structural formula V, when R 3 is acetoxy and R 1 , R 4 , and R 5 are hydrogen, hi another particular preferred embodiment the ⁇ 7 selective nicotinic agonist is a compound of structural formula V, when R 3 is methoxy and R 1 , R 4 , and R 5 are hydrogen, hi another particular preferred embodiment the ⁇ 7 selective nicotinic agonist is a compound of structural formula V, when R 3 is methoxy and R 1 and R 4 are hydrogen, and further when, R 3 is attached to the 2-position of the phenyl ring, and R 5 , which is attached to the 4-position of the phenyl ring, is methoxy or hydroxy.
- the ⁇ 7 selective nicotinic agonist is: 3-(2 5 4-dimethoxybenzylidine) anabaseine (GTS-21) (also known as DMXB-A), 3-(4-hydroxybenzylidene)anabaseine, 3-(4-methoxybenzylidene)anabaseine, 3-(4- aminobenzylidene)anabaseine, 3-(4-hydroxy-2-methoxybenzylidene)anabaseine, 3 -(4-methoxy-2-hydroxybenzylidene)anabaseine, trans-3 -cinnamylidene anabaseine, trans-3-(2-methoxy-cinnamylidene)anabaseine, or trans-3-(4-methoxycinnamylidene)anabaseine.
- GTS-21 also known as DMXB-A
- 3-(4-hydroxybenzylidene)anabaseine 3-(4-methoxybenzylidene)anabaseine
- ⁇ 7 selective nicotinic agonist is a compound of structural formula VI:
- VI X is O or S; R is H, OR 1 , ?MIC(O)R 1 , or a halogen; and R 1 is C r C 4 alkyl; or a pharmaceutically acceptable salt thereof.
- the ⁇ 7 selective nicotinic agonist is: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(4-hydroxyphenoxy)benzamide, N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(4-acetamidophenoxy)benzamide, N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(phenylsulfanyl)benzamide, or N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(3-chlorophenylsulphonyl)benzamide.
- the 7 selective nicotinic agonist is: GTS-21 , 3-(4-hydroxy-2-methoxybenzylidene)anabaseine, (R)-(-)-5 , -phenyls ⁇ iro[l-azabicyclo[2.2.2]octane-3,2 , octane-3,2 , (3 ⁇ )-furo[2,3-b] pyridine], (-)-spiro-[l-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one] or cocaine methiodide
- additional ⁇ 7 selective nicotinic agonist include trans-3-cinnamylidene anabaseine, trans-3-(2-methoxy-cinnamylidene)anabaseine or trans-3-(4- methoxycinnamylidene anabaseine
- the ⁇ 7 selective nicotinic agonist is an antibody which is a selective agonist (most preferably a specific agonist) for the cXl nicotinic receptor.
- the antibodies can be polyclonal or monoclonal; may be from human, non-human eukaryotic, cellular, fungal or bacterial sources; may be encoded by genomic or vector-borne coding sequences; and may be elicited against native or recombinant ⁇ 7 or fragments thereof with or without the use of adjuvants, all according to a variety of methods and procedures well-l iown in the art for generating and producing antibodies.
- the cc7 selective nicotinic agonist is an aptamer which is a selective agonist (more preferably a specific agonist) for the 7 nicotinic receptor.
- Aptamers are single stranded oligonucleotides or ohgonucleotide analogs that bind to a particular target molecule, such as a protein or a small molecule (e.g., a steroid or a drug, etc.).
- aptamers are the ohgonucleotide analogy to antibodies.
- aptamers are smaller than antibodies, generally in the range of 50-100 nt. Their binding is highly dependent on the secondary structure formed by the aptamer ohgonucleotide. Both ?RNA and single stranded DNA (or analog), aptamers are known. See, e.g., Burke et al., J. Mol. Biol, 264(4): 650-666 (1996); Ellington and Szostak, Nature, 346(6287): 818-822 (1990); Hirao et al, Mol Divers., 4(2): 75-89
- Aptamers can also be expressed from a transfected vector (Joshi et al, J. Virol, 76(13), 6545-6557 (2002)). Aptamers that bind to virtually any particular target can be selected by using an iterative process called SELEX, which stands for Systematic Evolution of Ligands by Exponential enrichment (Burke et al, J. Mol Biol, 264(4): 650-666
- the compounds can be administered in the form of a pharmaceutically acceptable salt.
- a pharmaceutically acceptable salt includes compounds disclosed herein which possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly can react with any of a number of organic or inorganic bases, and organic or inorganic acids, to form a salt.
- Acids commonly employed to form acid addition salts from compounds with basic groups are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as -toluenesulfonic acid, methanesulfonic acid, oxalic acid, ?-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
- organic acids such as -toluenesulfonic acid, methanesulfonic acid, oxalic acid, ?-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbut
- alkaline earth metal salts especially calcium and magnesium
- aluminum salts and ammonium salts as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'- dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2- hydroxyethyl)amine, procaine, dibenzylpiperidine, -benzyl- ⁇ -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N- methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine.
- physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexy
- alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties, typically C r C 10; preferably C r C 6 .
- al-kyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, and t-butyl.
- alkenyl as used herein, includes alkyl moieties, as defined above, having at least one carbon-carbon double bond. Examples of alkenyl groups include, but are not limited to, ethenyl and propenyl.
- alkynyl includes alkyl moieties, as defined above, having at least one carbon-carbon triple bond.
- al-kynyl groups include, but are not limited to, ethynyl and 2-propynyl.
- alkoxy means an "alkyl-O-" group, wherein alkyl is defined above.
- cycloalkyl includes non-aromatic saturated cyclic alkyl moieties, wherein alkyl is as defined above.
- cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- "Bicycloalkyl” groups are non-aromatic saturated carbocyclic groups consisting of two rings. Examples of bicycloalkyl groups include, but are not limited to, bicyclo-[2.2.2]-octyl and norbornyl.
- cycloalkenyl and “bicycloalkenyl” refer to non-aromatic carbocyclic, cycloalkyl, and bicycloaldkyl moieties as defined above, except comprising of one or more carbon-carbon double bonds connecting carbon ring members (an “endocyclic” double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon (an “exocyclic” double bond).
- Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl and cyclohexenyl.
- a non-limiting example of a bicycloalkenyl group is norborenyl.
- Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups similar to those described above for each of these respective categories, but which are substituted with one or more oxo moieties. Examples of such groups with oxo moieties include, but are not limited to, oxocyclopentyl, oxocyclobutyl, ococyclopentenyl, and norcamphoryl.
- cycloalkoxy includes “cycloalkyl-O-" group, wherein cycloalkyl is defined above.
- aryl refers to carbocyclic group.
- aryl groups include, but are not limited to, phenyl and naphthyl.
- heteroaryl refers to aromatic groups containing one or more heteroatoms (O, S, or ?N).
- a heteroaryl group can be monocyclic or polycyclic.
- the heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties.
- heteroaryl groups include, but are not limited to, pyridinyl, pyridazinal, imidaxolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, t-hiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothioph
- heteroaryl groups may be C-attached or N-attached (where such is possible).
- a group derived from pyrrole may be pyrrol- 1-yl (N-attached) or pyrrol-3-yl (C-attached).
- a bicyclic carbocyclic group is a bicyclic compound holding carbon only as a ring atom.
- the ring structure may in particular be aromatic, saturated, or partially saturated. Examples of such compounds include, but are not limited to, indanyl, naphthalenyl or azulenyl.
- an amino group may be primary (-
- ?MI 2 secondary (-?NHR a ), or tertiary (-?NR a R b ), wherein R ⁇ and R b may be: alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, heteroaryl, or a bicyclic carbocyclic group.
- activation of the cholinergic anti-inflammatory pathway, and the reduction of bleed time in a subject is achieved by indirect stimulation of the vagus nerve.
- the method comprises administering to the subject an effective amount of a non-steriodal anti-inflammatory drug (NSAID).
- NSAID non-steriodal anti-inflammatory drug
- Suitable NSAIDs include: aspirin, indomethacin, and ibuprofen.
- indirect stimulation of the vagus nerve is achieved by admimstering to the subject an effective amount of amiodarone or ⁇ -melanocyte-stimulating hormone (MSH).
- MSH ⁇ -melanocyte-stimulating hormone
- the route of administration of the pharmacological vagus nerve stimulators i.e., muscarinic agonists, NSAIDs, ⁇ MSH, and amiodarone
- the cholinergic agonists depends on the condition to be treated.
- the route of administration and the dosage to be administered can be determined by the skilled artisan without undue experimentation in conjunction with standard dose-response studies.
- compositions useful for the present invention can be administered parenterally such as, for example, by intravenous, intramuscular, intrathecal, or subcutaneous injection. Parenteral administration can be accomplished by incorporating the drug into a solution or suspension. Such solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, or other synthetic solvents.
- Parenteral formulations may also include antibacterial agents such as, for example, benzyl alcohol, or methyl parabens, antioxidants, such as, for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates, or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added.
- the parenteral preparation can be enclosed in ampules, disposable syringes, or multiple dose vials made of glass or plastic. Rectal administration includes administering the pharmaceutical compositions into the rectum or large intestine. This can be accomplished using suppositories or enemas. Suppository formulations can be made by methods known in the art.
- suppository formulations can be prepared by heating glycerin to about 120° C, dissolving the drug in the glycerin, mixing the heated glycerin after which purified water may be added, and pouring the hot mixture into a suppository mold.
- Transdermal administration includes percutaneous absorption of the drug through the sldn.
- Transdermal formulations include patches, ointments, creams, gels, salves, and the like, hi a preferred embodiment the cholinergic agonist, nicotine, is administered transdermally by means of a nicotine patch.
- a transesophageal device includes a device deposited on the surface of the esophagus which allows the drug contained within the device to diffuse into the blood which perfuses the esophageal tissue.
- the present invention includes nasally administering to the subject an effective amount of the drug.
- nasal administration includes administering the drug to the mucous membranes of the nasal passage or nasal cavity of the subject.
- pharmaceutical compositions for nasal administration of a drug include effective amounts of the drug prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream, or powder. Administration of the drug may also take place using a nasal tampon, or nasal sponge.
- compositions designed for oral, lingual, sublingual, buccal, and intrabuccal administration can be used with the disclosed methods and made without undue experimentation by means well -known in the art, for example, with an inert diluent or with an edible carrier.
- the compositions may be enclosed in gelatin capsules or compressed into tablets.
- the pharmaceutical compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums, and the like. Tablets, pills, capsules, troches, and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring agents.
- binders include microcrystalline cellulose, gum tragacanth, or gelatin.
- excipients include starch or lactose.
- disintegrating agents include alginic acid, corn starch, and the like.
- lubricants include magnesium stearate or potassium stearate.
- An example of a glidant is colloidal silicon dioxide.
- sweetening agents include sucrose, saccharin, and the like.
- flavoring agents include peppermint, methyl salicylate, orange flavoring, and the like. Materials used in preparing these various compositions should be pharmaceutically pure and nontoxic in the amounts used.
- Muscarinic agonists can be administered orally, parenterally, intranasally, vaginally, rectally, lingually, sublingually, buccaly, intrabuccaly, or transdermally to the subject as described above, provided the muscarinic agonist can cross the blood- brain barrier or permeate the brain through circumventricular organs which do not have a blood brain barrier.
- Brain muscarinic agonists can also be administered by intracerebro ventricular injection.
- NSAIDs, amiodarone, and ⁇ MSH may also be administered by intracerebro ventricular injection or by one of the techniques described above, provided that they can permeate the brain through the blood-brain barrier or tlrrough circumventricular organs which do not have a blood brain barrier.
- an effective amount is defined herein as a therapeutically or prophylactically sufficient amount of the drug to achieve the desired biological effect, here, the reduction of bleed time in a subject.
- Examples of effective amounts typically range from about 0.5 g / 25 g body weight to about 0.0001 ng / 25 g body weight, and preferably about 5 mg / 25 g body to about 1 ng / 25 g body weight.
- Yet another embodiment of the present invention is directed to methods of reducing bleed time in a subject. The methods comprise activating the cholinergic anti-inflammatory pathway by directly stimulating the vagus nerve.
- direct stimulation of the vagus nerve includes processes which involve direct contact with the vagus nerve or an organ served by the vagus nerve.
- vagus nerve is electrical stimulation of the vagus nerve.
- Direct stimulation of the vagus nerve releases acetylcholine which results in the reduction of bleed time in the brain or in peripheral organs served by the vagus nerve.
- the vagus nerve enervates principal organs including, the pharynx, the larynx, the esophagus, the heart, the lungs, the stomach, the pancreas, the spleen, the kidneys, the adrenal glands, the small and large intestine, the colon, and the liver.
- the vagus nerve can be stimulated by stimulating the entire vagus nerve (i.e., both the afferent and efferent nerves), or by isolating efferent nerves and stimulating them directly.
- the latter method can be accomplished by separating the afferent from the efferent fibers in an area of the nerve where both types of fibers are present.
- the efferent fiber is stimulated where no afferent fibers are present, for example close to the target organ served by the efferent fibers.
- the efferent fibers can also be stimulated by stimulating the target organ directly, e.g., electrically, thus stimulating the efferent fibers that serve that organ, hi other embodiments, the ganglion or postganglionic neurons of the vagus nerve can be stimulated.
- the vagus nerve can also be cut and the distal end can be stimulated, thus only stimulating efferent vagus nerve fibers.
- the vagus nerve can be directly stimulated by numerous methods. Nonlimiting examples include: mechanical means such as a needle, ultrasound, or vibration; electromagnetic radiation such as infrared, visible or ultraviolet light and electromagnetic fields; heat, or another energy source. Mechanical stimulation can also be carried out by carotid massage, oculocardiac reflex, dive reflex and valsalva maneuver.
- the efferent vagal nerve fibers can also be stimulated by electromagnetic radiation such as infrared, visible or ultraviolet light; heat, or any other energy source.
- the vagus nerve is directly stimulated electrically, using for example a commercial vagus nerve stimulator such as the Cyberonics NCP.RTM., or an electric probe.
- the amount of stimulation useful to reduce bleed time can be determined by the sldlled artisan without undue experimentation.
- Examples of effective amounts of electrical stimulation required to reduce bleed time include, but are not limited to, a constant voltage of 0.1, 0.5, 1, 2, 3, 5, or 10 V, at a pulse width of 2 ms and signal frequency of 1-5 Hz, for 5 seconds, 10 seconds, 30 seconds, 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, or 1 hour.
- the electrical stimulation required to reduce bleed time include, but are not limited to, a constant voltage of from about 0.01 to 1 V or from about 0.01 to 0.1 V or from about 0.01 to 0.05V; a signal current range from about 1 mA to about 100 mA, from about 1 mA to about 10 mA from about 1 mA to about 5 mA; a pulse width from about 0.1 to about 5 ms; signal frequencies of about 0.1 to about 30 Hz, or from about 1 to about 30 Hz, or from about 10 to about 30 Hz; a signal on-time from 1 to 120 seconds, or from about 10 to about 60 seconds, or from about 20 to about 40 seconds; signal off-time from 5 minutes, up to 2 hours, over 2 hours, over 4 hours, over 8 hours, over 12, hour, or from about 2 to about 48 hours, from about 4 to about 36 hours, from about 6 to about 36 hours from about 12 to about 36 hours, from about 16 to about 30 hours, from about 20 to about 28 hours.
- a constant voltage of from about
- signal off-time can be undefined as one sldlled in the art will readily determine the desired time interval between two consecutive signals. Examples include, signal voltage to a range from about 0.01 V to about 1 V; pulse width to a range from about 0.1 ms to about 5 ms; signal frequency to a range from about 0.1 Hz to about 30 Hz; signal on-time from about 1 second to about 120 seconds. Signal off-time can be undefined.
- a signal current from about 1 mA to about 5 mA; pulse width to a range from about 0.1 ms to about 0.5 ms; signal to a range of about 10 Hz to about 30 Hz; signal on-time to a range from about 20 seconds to about 40 seconds; signal off-time can be undefined.
- electrical vagal nerve stimulation which is sufficient to activate the cholinergic anti-inflammatory pathway in a subject does not decrease the heart rate of the subject.
- the vagus nerve is stimulated directly by means of an implanted device.
- the cholinergic anti-inflammatory pathway is activated by administering an effective amount of acetylcholinesterase inhibitor to the subject.
- acetylcholinesterase inliibitors include: tacrine, donepezil, rivastigmine, galantamine, metrifonate, physostigmine, neostigmine, edrophonium, pyridostigmine, demacarium, and ambenonium.
- the present invention is directed to reducing bleed time in a subject, the method comprising conditioning the subject to reduce bleed time by associating the activation of the cholinergic anti-inflammatory pathway with a sensory stimulus.
- Conditioning is a method of training an animal by which a perceptible neutral stimulus is temporarily associated with a physiological stimulus so that the animal will ultimately respond to the neutral stimulus as if it were the physiological stimulus.
- the present invention is directed to methods of conditioning a subject to reduce bleed time in the subject upon experiencing a sensory stimulus.
- the methods comprise the following steps: (a) activating the cholinergic anti-inflammatory pathway, and providing the sensory stimulus to the subject within a time period sufficient to create an association between the stimulus and the stimulation of the vagus nerve; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the bleed time to be reduced by the sensory stimulus alone.
- the CAP can be activated by any means previously discussed.
- the time interval between repetitions of the stimulus-activation procedures should also be short enough to optimize the reinforcement of the association.
- a common time interval is twice daily.
- the duration of the conditioning should also be sufficient to provide optimum reinforcement of the association.
- a common duration is at least one week. Optimum time intervals and durations can be determined by the sldlled artisan without undue experimentation by standard methods -known in the art.
- the sensory stimulus can be from any of the five senses.
- Nonlimiting examples of suitable sensory stimuli are sounds such as a bell ring, a buzzer, and a musical passage; a touch such as a pin stick, a feather touch, and an electric shock; a taste, or the ingestion of a particular chemical, such as a sweet taste, a sour taste, a salty taste, and saccharine ingestion; and a visual image such as a still picture, a playing card, or a short video presentation.
- the methods of the present invention are ideally suited to therapeutically or prophylactically treat subjects suffering from or at risk from suffering from excessive bleeding due to injury, surgery, or bleeding disorders such as: Hemophilia A, Hemophilia B, von Willebrand Disease, Afibrinogenemia, Factor II Deficiency, Parahemophilia, Factor VII Deficiency, Stuart Prower Factor Deficiency, Hageman Factor Deficiency, Fibrin Stabilizing Factor Deficiency, Thombophilia, heridetary platelet function disorders (for example: Bernard-Soulier Syndrome, Glanzmann Thrombasthenia, Gray Platelet Syndrome, Scott Syndrome, May-Hegglin Anomaly, Alport Syndrome and Wiskott-Aldrich Syndrome), or acquired platelet function disorders (such as those caused by common drugs: blood thinners, antibiotics and anaesthetics and those caused by medical conditions such as: leukemia, heart bypass surgery and c-hronic kidney disease).
- the method is
- Example 1 Reduction of bleed time in mouse model (male BALB/c mice) with electrical stimulation of the vagus nerve.
- the mice were divided into two groups, hi both groups the mice necks were dissected down to the musculature and the left vagus nerves were isolated. In the first group a 1 volt electric current was passed through the vagus nerve for 20 minutes. In the second group, the control group, the vagus nerve was isolated only, and the group was untreated for 20 minutes. The mice tails from both groups were warmed in 37°C saline for five minutes. The tails were then cut 2 mm from the tip, and the tail blood was collected in a 37°C saline solution. The results of the experiment are presented in Figure 1. Electrical stimulation of the vagus nerve significantly reduced bleed time in the mice compared with the control group, thus demonstrating that stimulation of the vagus nerve decreases peripheral bleed time in a subject.
- Example 2 Reduction in bleed time in mouse model (male BALB/c mice) with electrical stimulation of the vagus nerve.
- the mice were divided into two groups. In both groups the mice necks were dissected down to the musculature. The mice tails from both groups were warmed in 37°C saline for five minutes. hi both groups the left vagus nerves were isolated. In the first group a 1 volt electric current was passed through the vagus nerve for 30 seconds. The second group, the control group, was untreated for 30 seconds. The tails were then cut 2 mm from the tip, and the tail blood was collected in a 37°C saline solution. The results of this experiment are presented in Figure 2.
- Example 2 Two parameters in this example were changed from Example 1, firstly the duration of stimulation was decreased from 20 minutes to 30 seconds and secondly the mice tails were prewarmed prior to vagus nerve stimulation.
- the purpose of prewarming the mice tails prior to vagus nerve stimulation was to minimize the delay between stimulation and transection. This reduction in the delay between stimulation and transection resulted in a reduction in bleed time comparable with that shown in Example 1 where the mice tails were pre-warmed between the electrical stimulation and transection steps.
- Example 3 Reduction of bleed time in mouse model (male Balb/c mice) with administration of nicotine.
- mice were weighed, and ketamine (100 mg/kg) and xylazine (10 mg/kg) was administered to each mouse.
- the mice were then divided into two groups. After 20 minutes group one was injected with nicotine (0.3 mg/kg) and the second group, the control group was injected with saline.
- the nicotine solution was taken from a 162 mg/ml stock solution and diluted 1 : 10 in ethanol and then further diluted 1 :250 in phosphate buffer saline (PBS), bringing the final solution to 0.0648 ⁇ g/ ⁇ l; 115 ⁇ l/25 g mouse was injected into the mice. After five minutes the two groups were injected with a saline solution.
- PBS phosphate buffer saline
- mice tails from the two groups of mice were warmed by stirring in 37°C water.
- the tails were then cut 2 mm from the tip with a fresh scalpel.
- the tails were immediately immersed in a fluorescent activated sorting (FACS) tube which contained 3 ml pre-warmed saline.
- FACS fluorescent activated sorting
- the tubes were held in a beaker of 37°C water which was continuously stirred.
- the tails remained near the bottom of the tube the entire bleeding period.
- the bleeding time was counted using a stopwatch.
- the mice were then euthanized by CO 2 via a cardiac puncture with a heparinized needle.
- mice Male Balb/c mice (around 25 g) were injected (intraperitoneally (? ⁇ ?)) with cholinergic agonist GTS-21 (4mg/kg in 125 ⁇ L PBS) or PBS (vehicle control, 125 ⁇ L). 1 hour later, mice were anesthetized with ketamine/xylazine (100 mg/kg / 10 mg/kg, intraperitoneally ).
- Example 5 Coagulation cascade measurements Male Balb/c mice (around 25g) were subjected to either left vagus nerve isolation only (sham surgery) or left vagus nerve electrical stimulation (1 Volt, 2 ms pulse width, 1 Hz) for 30 seconds. Immediately following stimulation, animals were euthanized, and blood was obtained by cardiac puncture and analyzed with a Hemochron JR whole blood microcoagulation system (International Technidyne Corp, Edison NJ). Each specific test cuvette: Prothrombin Time (PT), Activated
- Partial Thromboplastin Time APTT
- Activated clotting time ACT is a self-contained disposable test chamber preloaded with a dried preparation of chemical reagents, stabilizers and buffers.
- the test cuvette was loaded with 50 ⁇ l of fresh whole blood. After mixing with cuvette reagents, the sample was monitored for clot formation until the clot endpoint value was achieved.
- Data are presented as mean +/- Standard Error of the Mean (SEM), and were analyzed by Student's t-test. The results are shown in Figures 5-7.
- Figures 5-7 demonstrate that the coagulation cascade is not significantly affected by vagus nerve stimulation.
- Example 7 Effect of administration of alpha-7 antagonist MLA on reduction of bleed time prior to administration of nicotine
- mice Male Balb/c mice (around 25g) were divided into three groups: A, B and C. Groups A and C were injected with the alpha-7 antagonist methyllycaconitine, (MLA; 4mg/kg, IP, in 200 ⁇ L PBS), group B was injected with PBS (vehicle control,
- MAA alpha-7 antagonist methyllycaconitine
- mice were anesthetized (ketamine [lOOmg/kg, IP] and xylazine [lOmg/kg, IP]).
Abstract
Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist acetylcholinesterase inhibitor to the subject.
Description
NEURAL TOURNIQUET
RELATED APPLICATION This application claims the benefit of U.S. Provisional Application No. 60/556,096, filed March 25, 2004. The entire teachings of the above application are incorporated herein by reference.
GOVERNMENT SUPPORT The invention was supported, in whole or in part, by a grant N66001-03-1- 8907 P00003 from Space and Naval Warfare Systems Center-San Diego and Defense Advanced Research Programs Agency. The Government has certain rights * in the invention.
BACKGROUND OF THE INVENTION Excessive bleeding can occur as a consequence of injury, surgery, inherited bleeding disorders, or bleeding disorders which are developed during certain illnesses (such as vitamin K deficiency, severe liver damage) or treatments (such as the use of anticoagulant drugs or prolonged use of antibiotics). Some of the risks associated with bleeding disorders include scarring of the joints or joint disease, vision loss from bleeding into the eye, chronic anemia from blood loss, and death which may occur with large amounts of blood loss or bleeding in critical areas such as the brain. Bleeding disorders result from an inability of the blood to clot. This inability is most commonly caused by a deficiency of blood coagulation factors. Other less common causes include a deficiency in blood platelets or a disorder in platelet
function. Hemophilia A is one of the most frequently occurring inherited coagulation disorders. Patients with hemophilia A are prone to frequent hemorrhages as a result of a deficiency in Factor NHL Common treatments for people with bleeding disorders such as hemophilia A, include factor replacement therapy. This is the injection into the bloodstream of Factor N-ffl concentrates to prevent or control bleeding. Factor replacement therapy can also be used to reduce postoperative bleeding in high risk surgical procedures. The main disadvantage of factor replacement therapy, however, is the increased risk of exposure to blood-borne infections such as hepatitis due to infusions of blood products.
SUMMARY OF THE INVENTION It has now been discovered that bleed time can be reduced in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct stimulation of the vagus nerve in the subject. For example, it has been shown by the inventor that electrical stimulation of the vagus nerve leads to decreased bleed time in laboratory mice (see Examples 1 and 2). The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of a cholinergic agonist to the subject. For example, it has been further shown by the inventor that administration of nicotine to laboratory mice, decreases bleed time in the mice (see Example 3). Based on these discoveries methods of reducing bleed time in a subject in need of such treatment are disclosed herein. One embodiment of the present invention is a method of reducing bleed time in a subject by activating the cholinergic anti-inflammatory pathway. For example, the cholinergic anti-inflammatory pathway can be activated by stimulating the vagus nerve in the subject. The vagus nerve can be indirectly stimulated by administering an effective amount of muscarinic agonist to the subject. Suitable examples of muscarinic agonists include: muscarine, McN-A-343, MT-3 and CNI-1493. The cholinergic anti-inflammatory pathway can also be activated by administering an
effective amount of cholinergic agonist to the subject. One example of a suitable cholinergic agonist is nicotine. Most preferably, the cholinergic agonist is selective for an α-7 nicotinic receptor; examples of suitable α-7 selective nicotinic agonists include: GTS-21, 3-(4-hydroxy-2-methoxybenzylidene) anabaseine, choline, cocaine methiodide, trans-3-cinnamylidene anabaseine, trans-3-(2-methoxy- cinnamylidene)anabaseine, or trans-3-(4-methoxycinnamylidene)anabaseine. The cholinergic anti-inflammatory pathway can also be activated by electrical stimulation of the vagus nerve in the subject or mechanical stimulation of the vagus nerve.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph showing the decrease in bleed time in seconds in laboratory mice, after vagus nerve stimulation at 1 volt for 20 minutes. This result is compared to a longer bleed time in a control group in which the vagus nerve was isolated but not stimulated. Figure 2 is a graph showing the decrease in bleed time in seconds in laboratory mice, after vagus nerve stimulation at 1 volt for 30 seconds. This result is compared to a longer bleed time in a control group in which the vagus nerve was isolated but not stimulated. Figure 3 is a graph showing the decrease in bleed time in seconds in laboratory mice after administration of nicotine. This result is compared to a longer bleed time in a control group to which a saline solution was administered. Figure 4 is a graph showing the decrease in bleed time in seconds in two groups of laboratory mice after tail amputation. The first group was administered
GTS-21 prior to amputation; a control group was administered saline. Figure 5 is a graph showing the prothrombin time in (PT) seconds in laboratory mice after electrical vagus nerve stimulation (1 V, 2 ms pulse width, 1Hz for 30 seconds). Figure 6 is a graph showing the activated partial thromboplastin (APTT) time in seconds in laboratory mice after electrical vagus nerve stimulation (IV, 2 ms pulse width, 1Hz for 30 seconds).
Figure 7 is a graph showing the activated clotting time (ACT) in seconds in laboratory mice after electrical vagus nerve stimulation (IV, 2 ms pulse width, 1Hz for 30 seconds). Figure 8 is a graph showing the decrease in bleed time in seconds in conscious laboratory mice after administration of nicotine. This result is compared to a longer bleed time in a control group to which a saline solution was administered. Figure 9 is a graph showing the effect of administration of the alpha-7 antagonist MLA to mice prior to administration of nicotine.
DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the discovery that bleed time can be reduced in a subject by activation of the cholinergic anti-inflammatory pathway (CAP) in said subject. As used herein, a subject is preferably a mammal, more preferably a human patient but can also be a companion animal (e.g., dog or cat), a farm animal (e.g., horse, cow, or sheep) or a laboratory animal (e.g., rat, mouse, or guinea pig). The cholinergic anti-inflammatory pathway, as used herein, refers to a biochemical pathway in a subject, that is activated by cholinergic agonists and reduces inflammation in the subject. The cholinergic anti-inflammatory pathway is described in U.S. Patent Publication No. 2004/0204355 filed December 5, 2003 and
U.S. Patent No. 6,610,713 filed May 15, 2001, the entire teachings of each of which are incorporated herein by reference. It has now been found that activation of the cholinergic anti-inflammatory pathway also results in the reduction of bleed time in a subject. The cholinergic anti-inflammatory pathway may also be activated by stimulation (direct or indirect) of the vagus nerve in a subject. It is well known in the art that stimulation of the vagus nerve results in the release acetylcholine from efferent vagus nerve fibers (this is described in U.S. Patent 6,610,713 B2, filed May 15, 2001, the entire teachings of which are incorporated herein by reference). As used herein, the vagus nerve includes nerves that branch off from the main vagus
nerve, as well as ganglions or postganglionic neurons that are connected to the vagus nerve. The effect of vagus nerve stimulation on bleed time is not necessarily limited to that caused by acetylcholine release. The scope of the invention also encompasses other mechanisms which are partly or wholly responsible for the reduction of bleed time by vagus nerve stimulation. Nonlimiting examples include the release of serotonin agonists or stimulation of other neurotransmitters. The terms 'reduce' or 'reduced' when referring to bleed time in a subject, encompass at least a small but measurable reduction in bleed time over non-treated controls. In preferred embodiments, the bleed time is reduced by at least 20% over non-treated controls; in more preferred embodiments, the reduction is at least 70%; and in still more preferred embodiments, the reduction is at least 80%. In one embodiment of the present invention, activation of the cholinergic anti-inflammatory pathway, and the reduction of bleed time in a subject is achieved by indirect stimulation of the vagus nerve. As used herein, indirect stimulation includes methods which involve secondary processes or agents which stimulate the vagus nerve. One example of such a secondary agent is a pharmacological vagus nerve stimulator. In a preferred embodiment the pharmacological vagus nerve stimulator is an agonist (such as a muscarinic agonist) that activates a muscarinic receptor in the brain. As used herein, a muscarinic agonist is a compound that can bind to and activate a muscarinic receptor to produce a desired physiological effect, here, the reduction of bleed time. A muscarinic receptor is a cholinergic receptor which contains a recognition site for a muscarinic agonist (such as muscarine). hi one embodiment, the muscarinic agonist is non-selective and can bind to other receptors in addition to muscarinic receptors, for example, another cholinergic receptor. An example of such a muscarinic agonist is acetylcholine. In a preferred embodiment, the muscarinic agonist binds muscarinic receptors with greater affinity than other cholinergic receptors, for example, nicotinic receptors (for example with at least 10% greater affinity, 20% greater affinity, 50% greater affinity, 75%) greater affinity, 90%) greater affinity, or 95% greater affinity).
In a preferred embodiment the muscarinic agonist is selective for an Ml, M2, or M4 muscarinic receptor (as disclosed in U.S. Patent No. 6,602,891, U.S. Patent No. 6,528,529, U.S. Patent No. 5,726,179, U.S. Patent No. 5,718,912, U.S. Patent No. 5,618,818, U.S. Patent No. 5,403,845, U.S. Patent No. 5,175,166, U.S. Patent No. 5,106,853, U.S. Patent No. 5,073,560 and U.S. Patent Publication No. 2004/0048795 filed February 26, 2003, the contents of each of which are incorporated herein by reference in their entirety). As used herein, an agonist that is selective for an Ml, M2, or M4 receptor is an agonist that binds to an Ml, M2, and/or M4 receptor with greater affinity than it binds to at least one, or at least two, or at least five other muscarinic receptor subtypes (for example, M3 or M5 muscarinic receptors) and/or at least one, or at least two, or at least five other cholinergic receptors, hi a preferred embodiment, the agonist binds with at least 10% greater affinity, 20%> greater affinity, 50% greater affinity, 75%> greater affinity, 90% greater affinity, or 95%> greater affinity than it binds to muscarinic and/or cholinergic receptor subtypes other than Ml, M2, and/or M4 receptors. Binding affinities can be determined using receptor binding assays known to one of skill in the art. Nonlimiting examples of preferred muscarinic agonists useful for these methods include: muscarine, McN-A-343, and MT-3. In a most preferred embodiment, the muscarinic agonist is N,N'-bis (3,5-diacetylphenyl) decanediamide tetrakis (amidmohydrazone) tetrahydrochloride (CM- 1493), w-hich has the following structural formula:
In another embodiment, the muscarinic agonist is a CM- 1493 compound. As used herein, a CM- 1493 compound is an aromatic guanylhydrazone (more properly termed amidmohydrazone, i.e., ?NH2(C?NH)-? H-N=), for example, a compound having the structural formula I:
I
X2 is NH2(CNH)-NH-N=CH-, NΗ2(CMΪ)-NH-N=CCH3-, or H-; X„ X^ and X'2 independently are ?MI2(CNH)-NH-N=CH- or NH2(CMΪ)-NH-N=CCH3-; Z is -NH(CO)NH-, -(C6H4)-, -(C5?Ml3)-, or - A-(CH2)n-A-, n is 2- 10, which is unsubstituted, mono- or di-C-methyl substituted, or a mono or di- unsaturated derivative thereof; and A, independently, is -NH(CO)-, -NH(CO)NH-, -NH-, or -O-, and pharmaceutically acceptable salts thereof. A preferred embodiment includes those compounds where A is a single functionality. Also included are compounds having the structural formula I when Xx and X2 are H; X', and X'2 independently are
-NH2(C?MΪ)-NH-N=CH- or -NH2(CNH)-NH-N=CCH3-; Z is -A-(CH2)n-A-, n is 3-8; A is -? H(CO)- or -? H(CO)? H-; and pharmaceutically acceptable salts thereof. Also included are compounds of structural formula I when Xj and X2 are H; X and X'2 independently are ?NH2(CNH)-NH-N=CH- or -NH2(CNH)-NH-N=CCH3-; Z is -O- (CH2)2-O-; and pharmaceutically acceptable salts thereof. Further examples of CM- 1493 compounds include compounds of structural formula I when X2 is NH2(CNH)-NH-N=CH-, NH2(CNH)-MT-N=CCH3- or H-; Xl5 X1 ! and X'2 are NH2(C?NH)-NH-N=CH- or NH2(CNH)-NH-N=CCH3-; and Z is -O-(CH2)n-O-, n is 2-10; pharmaceutically acceptable salts thereof; and the related genus, when X2 is other than H, X2 is meta or para to Xl and when, X'2 is meta or para to X . Another embodiment includes a compound having structural formula I when X2 is NH2(CNH)-NH-N=CH-, NH2(CMΪ)-MΪ-N=CCΗ3-, or H; Xl5 X^ and X'2, are NH2(CMT)-MI-N=CH- or NH2(CNH)-MΪ-N=CCH3-; Z is -NH- (C=O)-
?NH-; pharmaceutically acceptable salts thereof; and the related genus when X2 is other than H, X2 is meta or para to Xt and when X'2 is meta or para to X A CM- 1493 compound also includes an aromatic guanylhydrazone compound having the structural formula II:
π
Xlt X2; and X3 independently are NH2(CNH)-NH-N=CH- or NH2(CNH)-NH- N=CCH3-, X , X*2, and X'3 independently are H, NH2(CNH)-NH-N=CH- or NH2(CNH)-NH-N=CCH3-; Z is (C6H3), when ml5 m2, and m3 are 0 or Z is N, when, independently, ml5 m2, and m3 are 2-6, and A is -NH(CO)-, -NH(CO)NH-, -NH-, or
-O-; and pharmaceutically acceptable salts thereof. Further examples of compounds of structural formula II include the genus wherein, when any of X'l9 X'2, and X'3 are other than H, then the corresponding substituent of the group consisting of X X2, and X3 is meta or para to X'„ X'2, and X'3, respectively; the genus when ml5 m2, and m3 are 0 and A is -NH(CO)-; and the genus when ml5 m2, and m3 are 2-6, A is
-?Mϊ(CO)?MH-, and pharmaceutically acceptable salts thereof. Examples of CM- 1493 compounds and methods for making such compounds are described in U.S. Patent No. 5,854,289 (the contents of which are incorporated herein by reference).
Alternatively, the cholinergic anti-inflammatory pathway is activated by administering an effective amount of cholinergic agonist to a subject, thus reducing bleed time in said subject. As used herein, a cholinergic agonist is a compound that binds to and activates a cholinergic receptor producing a desired physiological effect, here, the reduction of bleed time in a subject. The sldlled artisan can determine whether any particular compound is a cholinergic agonist by any of several well -known methods, hi preferred embodiments the cholinergic agonist has been used therapeutically in vivo or is naturally produced. Nonlimiting examples of cholinergic agonists suitable for use in the disclosed invention include: acetylcholine, nicotine, muscarine, carbachol, galantamine, arecoline, cevimeline, and levamisole. In a preferred embodiment the cholinergic agonist is acetylcholine, nicotine, or muscarine. In a more preferred embodiment the cholinergic agonist is an α7 selective nicotinic cholinergic agonist. As used herein an α7 selective nicotinic cholinergic agonist is a compound that selectively binds to and activates an α7 nicotinic cholinergic receptor in a subject. Nicotinic cholinergic receptors are a family of ligand-gated, peiitameric ion channels. In humans, 16 different subunits (αl-7, <x9- 10, βl-4, δ, e, and γ) have been identified that form a large number of homo- and hetero-pentameric receptors with distinct structural and pharmacological properties (Lindstrom, J.M., Nicotinic Acetylcholine Receptors. In "Hand Book of Receptors and Channels: Ligand- and Voltage-Gated Ion Channels" Edited by R. Alan North CRC Press Inc., (1995); Leonard, S., & Bertrand, D., Neuronal nicotinic receptors: from structure to function. Nicotine & Tobacco Res. 3:203-223 (2001); Le Novere, N., & Changeux, J-P., Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells, J. Mol. Evol, 40: 155-172 (1995)). As used herein, a cholinergic agonist is selective for an α7 nicotinic cholinergic receptor if that agonist activates an α7 nicotinic cholinergic receptor to a greater extent than the agonist activates at least one other nicotinic receptor. It is preferred that the α7 selective nicotinic agonist activates the α7 nicotinic receptor at least two-fold, at least five-fold, at least ten-fold, and most preferably at least fifty-
fold more than at least one other nicotinic receptor (and preferably at least two, three, or five other nicotinic receptors). Most preferably, the α7 selective nicotinic agonist will not activate another nicotinic receptor to any measurable degree (i.e., significant at P = 0.05 vs. untreated receptor in a well-controlled comparison). Such an activation difference can be measured by comparing activation of the various receptors by any -known method, for example using an in vitro receptor binding assay, such as those produced by NovaScreen Biosciences Corporation (Hanover MD), or by the methods disclosed in WO 02/44176 (α4β2 tested), U.S. Patent No. 6,407,095 (peripheral nicotinic receptor of the ganglion type), U.S. Patent Application Publication No. 2002/0086871 (binding of labeled ligand to membranes prepared from GH4C1 cells transfected with the receptor of interest), and WO 97/30998. References which describe methods of determining agonists that are selective for α7 receptors include: U.S. Patent No. 5,977,144 (Table 1), WO 02/057275 (pg 41-42), and Holladay et al, Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery, Journal of Medicinal Chemistry, 40:4169-
4194 (1997), the teachings of these references are incorporated herein by reference in their entirety. Assays for other nicotinic receptor subtypes are known to the sldlled artisan. In one embodiment the α7 selective nicotinic agonist is a compound of structural formula HI:
R is hydrogen or methyl, and n is 0 or 1, and pharmaceutically acceptable salts thereof, hi a preferred embodiment the α7 selective nicotinic agonist is (-)- spiro[l-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one]. Methods of preparation of compounds of structural formula in are described in U.S. Patent No. 5,902,814, the contents of which are incorporated herein by reference in their entirety. hi another embodiment, the 7 selective nicotinic agonist is a compound of structural formula -TV:
m is 1 or 2; n is 0 or 1; Y is CH, N or NO; X is oxygen or sulfur; W is oxygen, H2 or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G and D is nitrogen but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or to C4 alkyl, R2, R3, and R4 are independently hydrogen, halogen, Cj- alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC C4 alkyl, CO^ -CN, -NO2, -NR5 R6, -CF3ι or -OSO2CF3, or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substitutents: independently hydrogen, halogen, - alkyl, C2-C4 alkenyl, C2-C4
alkynyl, aryl, heteroaryl, OH, OCrC4 alkyl, COjR1, -CN, -NO2, -NR5R6, -CF3, or - OSO2CF3; R5 and R6 are independently hydrogen, CrC4 allcyl, C(O)R7, C(O)NHR8, C(O)OR9, SO2R10 or may together be (CR2)jQ(Cli2)k, where Q is O, S, NR11, or a bond; j is 2 to 7; k is 0 to 2; and R7, R8, R9, R10 and R" are independently C,-C4, alkyl, aryl, or heteroaryl; an enantiomer thereof, or a pharmaceutically acceptable salt thereof, hi preferred embodiments, the α7 selective nicotinic agonist is a compound of structural formula IV when m is 2; n is 0; X is oxygen; A is C(R2); G is C(R3); and D is C(R4). In a particular preferred embodiment the α7 selective nicotinic agonist is (R)-(-)-5'-phenylspiro[l-aziobicyclo[2.2.2]octane-3,2'(3'H)- furo[2,3-b]pyridine]. Methods of preparation of compounds of structural formula IV are described in the U.S. Patent No. 6,110,914, the contents of which are incorporated herein by reference in their entirety. In yet another embodiment the α7 selective nicotinic agonist is a compound of structural formula V:
V
R1, R6 and R7 are hydrogen or CrC4 alkyl; alternatively R1 is hydrogen or C C4 alkyl, and R6 and R7 are absent, hydrogen or CrC4 alkyl; and R2 is:
or
R3, R4, and R5 are hydrogen, Cj- alkyl optionally substituted with N,N- dialkylamino having 1 to 4 carbons in each of the alkyls, CrC6 alkoxy optionally substituted withN, N-dialkylamino having 1 to 4 carbons in each of the alkyls, carboalkoxy having 1 to 4 carbons in the alkoxy, amino, amido having 1 to 4 carbons in the acyl, cyano, and N,N-dialkylamino having 1 to 4 carbons in each of the alkyls, halo, hydroxyl or nitro. In preferred embodiments, the α7 selective nicotinic agonist is a compound of structural formula V when R2 is attached to the 3-position of the tetrahydropyridine ring. In another preferred embodiment when R3, which may preferably be attached to the 4- or the 2-position of the phenyl ring, is: amino, hydroxyl, chloro, cyano, dimethylamino, methyl, methoxy, acetylamino, acetoxy, or nitro. 3h one particular preferred embodiment the α7 selective nicotinic agonist is a compound of structural formula V, when R3 is hydroxyl, and R1, R4, and R5 are hydrogen, hi another particular preferred embodiment the α7 selective nicotimc agonist is a compound of structural formula V, when R3 is acetylamino and R1, R4, and R5 are hydrogen. In another particular preferred embodiment the α7 selective
nicotinic agonist is a compound of structural formula V, when R3 is acetoxy and R1, R4, and R5 are hydrogen, hi another particular preferred embodiment the α7 selective nicotinic agonist is a compound of structural formula V, when R3 is methoxy and R1, R4, and R5 are hydrogen, hi another particular preferred embodiment the α7 selective nicotinic agonist is a compound of structural formula V, when R3 is methoxy and R1 and R4 are hydrogen, and further when, R3 is attached to the 2-position of the phenyl ring, and R5, which is attached to the 4-position of the phenyl ring, is methoxy or hydroxy. ?hι a preferred embodiment the α7 selective nicotinic agonist is: 3-(254-dimethoxybenzylidine) anabaseine (GTS-21) (also known as DMXB-A), 3-(4-hydroxybenzylidene)anabaseine, 3-(4-methoxybenzylidene)anabaseine, 3-(4- aminobenzylidene)anabaseine, 3-(4-hydroxy-2-methoxybenzylidene)anabaseine, 3 -(4-methoxy-2-hydroxybenzylidene)anabaseine, trans-3 -cinnamylidene anabaseine, trans-3-(2-methoxy-cinnamylidene)anabaseine, or trans-3-(4-methoxycinnamylidene)anabaseine. Methods of preparation of compounds of structural formula V are described in U.S. Patent No. 5,977,144, and U.S. Patent No. 5,741,802 the contents of each of which are incorporated herein by reference in their entirety. In further embodiments the α7 selective nicotinic agonist is a compound of structural formula VI:
VI X is O or S; R is H, OR1, ?MIC(O)R1, or a halogen; and R1 is CrC4 alkyl; or a pharmaceutically acceptable salt thereof. In a particular preferred embodiment the α7 selective nicotinic agonist is:
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(4-hydroxyphenoxy)benzamide, N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(4-acetamidophenoxy)benzamide, N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(phenylsulfanyl)benzamide, or N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(3-chlorophenylsulphonyl)benzamide. Methods of preparation of compounds with structural formula VI have been described in the U.S. Patent Application 2002/0040035, the contents of which are incorporated herein by reference in their entirety. hi yet another embodiment the α7 selective nicotinic agonist is (1-aza-bicyclo [2.2.2] oct-3-yl)-carbamic acid l-(2-fluorophenyl)-ethyl ester. Methods of preparation of this compound have been described in the U.S. Patent
Application Publication 2002/0040035, the contents of which are incorporated herein by reference in their entirety. hi an even more preferred embodiment the 7 selective nicotinic agonist is: GTS-21 , 3-(4-hydroxy-2-methoxybenzylidene)anabaseine, (R)-(-)-5,-phenylsρiro[l-azabicyclo[2.2.2]octane-3,2,octane-3,2,(3Η)-furo[2,3-b] pyridine], (-)-spiro-[l-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one] or cocaine methiodide, additional α7 selective nicotinic agonist include trans-3-cinnamylidene anabaseine, trans-3-(2-methoxy-cinnamylidene)anabaseine or trans-3-(4- methoxycinnamylidene anabaseine. In yet another embodiment, the α7 selective nicotinic agonist is an antibody which is a selective agonist (most preferably a specific agonist) for the cXl nicotinic receptor. The antibodies can be polyclonal or monoclonal; may be from human, non-human eukaryotic, cellular, fungal or bacterial sources; may be encoded by genomic or vector-borne coding sequences; and may be elicited against native or recombinant α7 or fragments thereof with or without the use of adjuvants, all according to a variety of methods and procedures well-l iown in the art for generating and producing antibodies. Other examples of such useful antibodies include but are not limited to chimeric, single-chain, and various human or humanized types of antibodies, as well as various fragments thereof such as Fab fragments and fragments produced from specialized expression systems.
n additional embodiments, the cc7 selective nicotinic agonist is an aptamer which is a selective agonist (more preferably a specific agonist) for the 7 nicotinic receptor. Aptamers are single stranded oligonucleotides or ohgonucleotide analogs that bind to a particular target molecule, such as a protein or a small molecule (e.g., a steroid or a drug, etc.). Thus aptamers are the ohgonucleotide analogy to antibodies.
However, aptamers are smaller than antibodies, generally in the range of 50-100 nt. Their binding is highly dependent on the secondary structure formed by the aptamer ohgonucleotide. Both ?RNA and single stranded DNA (or analog), aptamers are known. See, e.g., Burke et al., J. Mol. Biol, 264(4): 650-666 (1996); Ellington and Szostak, Nature, 346(6287): 818-822 (1990); Hirao et al, Mol Divers., 4(2): 75-89
(1998) ; Jaeger et al, The EMBO Journal 17(15): 4535-4542 (1998) ; Kensch et al, J. Biol. Chem., 275(24): 18271-18278 (2000); Schneider et al., Biochemistry, 34(29): 9599-9610 (1995); and U.S. Patent Nos.: 5,496,938; 5,503,978; 5,580,737; 5,654,151; 5,726,017; 5,773,598; 5,786,462; 6,028,186; 6,110,900; 6,124,449; 6,127,119; 6,140,490; 6,147,204; 6,168,778; and 6,171,795. Aptamers can also be expressed from a transfected vector (Joshi et al, J. Virol, 76(13), 6545-6557 (2002)). Aptamers that bind to virtually any particular target can be selected by using an iterative process called SELEX, which stands for Systematic Evolution of Ligands by Exponential enrichment (Burke et al, J. Mol Biol, 264(4): 650-666
(1996); Ellington and Szostak, Nature, 346(6287): 818-822 (1990); Schneider et al, Biochemistry, 34(29): 9599-9610 (1995); Tuerk et al, Proc. Natl Acad. Sci. USA, 89: 6988-6992 (1992); Tuerk and Gold, Science, 249(4968): 505-510 (1990)). Several variations of SELEX have been developed which improve the process and allow its use under particular circumstances. See, e.g., U.S. Patent. Nos.: 5,472,841;
5,503,978; 5,567,588; 5,582,981; 5,637,459; 5,683,867; 5,705,337; 5,712,375; and 6,083,696. Thus, the production of aptamers to any particular oligopeptide, including the cXI nicotinic receptor, requires no undue experimentation. As described above, the compounds can be administered in the form of a pharmaceutically acceptable salt. This includes compounds disclosed herein which
possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly can react with any of a number of organic or inorganic bases, and organic or inorganic acids, to form a salt. Acids commonly employed to form acid addition salts from compounds with basic groups, are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as -toluenesulfonic acid, methanesulfonic acid, oxalic acid, ?-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene- 1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like. Such a pharmaceutically acceptable salt may be made with a base which affords a pharmaceutically acceptable cation, which includes alkali metal salts
(especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'- dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2- hydroxyethyl)amine, procaine, dibenzylpiperidine, -benzyl-β-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N- methylglucamine, collidine, quinine, quinoline, and basic amino acid such as lysine and arginine. These salts may be prepared by methods known to those skilled in the art.
The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties, typically CrC10; preferably CrC6. Examples of al-kyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, and t-butyl. The term "alkenyl", as used herein, includes alkyl moieties, as defined above, having at least one carbon-carbon double bond. Examples of alkenyl groups include, but are not limited to, ethenyl and propenyl. The term "alkynyl", as used herein, includes alkyl moieties, as defined above, having at least one carbon-carbon triple bond. Examples of al-kynyl groups include, but are not limited to, ethynyl and 2-propynyl. The term "alkoxy", as used herein, means an "alkyl-O-" group, wherein alkyl is defined above. The term "cycloalkyl", as used herein, includes non-aromatic saturated cyclic alkyl moieties, wherein alkyl is as defined above. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. "Bicycloalkyl" groups are non-aromatic saturated carbocyclic groups consisting of two rings. Examples of bicycloalkyl groups include, but are not limited to, bicyclo-[2.2.2]-octyl and norbornyl. The term "cycloalkenyl" and "bicycloalkenyl" refer to non-aromatic carbocyclic, cycloalkyl, and bicycloaldkyl moieties as defined above, except comprising of one or more carbon-carbon double bonds connecting carbon ring members (an "endocyclic" double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon (an "exocyclic" double bond). Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl and cyclohexenyl. A non-limiting example of a bicycloalkenyl group is norborenyl. Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups similar to those described above for each of these respective categories, but which are substituted with one or more oxo moieties. Examples of such groups with oxo moieties include, but are not limited to, oxocyclopentyl, oxocyclobutyl, ococyclopentenyl, and norcamphoryl.
The term "cycloalkoxy", as used herein, includes "cycloalkyl-O-" group, wherein cycloalkyl is defined above. The term "aryl", as used herein, refers to carbocyclic group. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. The term "heteroaryl", as used herein, refers to aromatic groups containing one or more heteroatoms (O, S, or ?N). A heteroaryl group can be monocyclic or polycyclic. The heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinal, imidaxolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, t-hiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotirazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furophridinyl, pyrolopyrimidinyl, and azaindoyl. The foregoing heteroaryl groups may be C-attached or N-attached (where such is possible). For instance, a group derived from pyrrole may be pyrrol- 1-yl (N-attached) or pyrrol-3-yl (C-attached). -hi the context of the present invention, a bicyclic carbocyclic group is a bicyclic compound holding carbon only as a ring atom. The ring structure may in particular be aromatic, saturated, or partially saturated. Examples of such compounds include, but are not limited to, indanyl, naphthalenyl or azulenyl. In the context of the present invention, an amino group may be primary (-
?MI2), secondary (-?NHRa), or tertiary (-?NRaRb), wherein R^ and Rb may be: alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, heteroaryl, or a bicyclic carbocyclic group. hi another embodiment, activation of the cholinergic anti-inflammatory pathway, and the reduction of bleed time in a subject is achieved by indirect
stimulation of the vagus nerve. The method comprises administering to the subject an effective amount of a non-steriodal anti-inflammatory drug (NSAID). Examples of suitable NSAIDs include: aspirin, indomethacin, and ibuprofen. Alternatively, indirect stimulation of the vagus nerve is achieved by admimstering to the subject an effective amount of amiodarone or α-melanocyte-stimulating hormone (MSH). The route of administration of the pharmacological vagus nerve stimulators (i.e., muscarinic agonists, NSAIDs, αMSH, and amiodarone) and the cholinergic agonists depends on the condition to be treated. The route of administration and the dosage to be administered can be determined by the skilled artisan without undue experimentation in conjunction with standard dose-response studies. Relevant circumstances to be considered in making those determinations include the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual subject, and the severity of the subject's symptoms. Compositions useful for the present invention can be administered parenterally such as, for example, by intravenous, intramuscular, intrathecal, or subcutaneous injection. Parenteral administration can be accomplished by incorporating the drug into a solution or suspension. Such solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, or other synthetic solvents.
Parenteral formulations may also include antibacterial agents such as, for example, benzyl alcohol, or methyl parabens, antioxidants, such as, for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates, or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added. The parenteral preparation can be enclosed in ampules, disposable syringes, or multiple dose vials made of glass or plastic. Rectal administration includes administering the pharmaceutical compositions into the rectum or large intestine. This can be accomplished using suppositories or enemas. Suppository formulations can be made by methods known in the art. For example, suppository formulations can be prepared by heating
glycerin to about 120° C, dissolving the drug in the glycerin, mixing the heated glycerin after which purified water may be added, and pouring the hot mixture into a suppository mold. Transdermal administration includes percutaneous absorption of the drug through the sldn. Transdermal formulations include patches, ointments, creams, gels, salves, and the like, hi a preferred embodiment the cholinergic agonist, nicotine, is administered transdermally by means of a nicotine patch. A transesophageal device includes a device deposited on the surface of the esophagus which allows the drug contained within the device to diffuse into the blood which perfuses the esophageal tissue. The present invention includes nasally administering to the subject an effective amount of the drug. As used herein, nasal administration includes administering the drug to the mucous membranes of the nasal passage or nasal cavity of the subject. As used herein, pharmaceutical compositions for nasal administration of a drug include effective amounts of the drug prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream, or powder. Administration of the drug may also take place using a nasal tampon, or nasal sponge. Accordingly, drug compositions designed for oral, lingual, sublingual, buccal, and intrabuccal administration can be used with the disclosed methods and made without undue experimentation by means well -known in the art, for example, with an inert diluent or with an edible carrier. The compositions may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the pharmaceutical compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums, and the like. Tablets, pills, capsules, troches, and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring agents. Some examples of binders include microcrystalline cellulose, gum tragacanth, or gelatin. Examples of excipients include starch or lactose. Some examples of
disintegrating agents include alginic acid, corn starch, and the like. Examples of lubricants include magnesium stearate or potassium stearate. An example of a glidant is colloidal silicon dioxide. Some examples of sweetening agents include sucrose, saccharin, and the like. .Examples of flavoring agents include peppermint, methyl salicylate, orange flavoring, and the like. Materials used in preparing these various compositions should be pharmaceutically pure and nontoxic in the amounts used. Muscarinic agonists, can be administered orally, parenterally, intranasally, vaginally, rectally, lingually, sublingually, buccaly, intrabuccaly, or transdermally to the subject as described above, provided the muscarinic agonist can cross the blood- brain barrier or permeate the brain through circumventricular organs which do not have a blood brain barrier. Brain muscarinic agonists can also be administered by intracerebro ventricular injection. NSAIDs, amiodarone, and αMSH may also be administered by intracerebro ventricular injection or by one of the techniques described above, provided that they can permeate the brain through the blood-brain barrier or tlrrough circumventricular organs which do not have a blood brain barrier. An effective amount, is defined herein as a therapeutically or prophylactically sufficient amount of the drug to achieve the desired biological effect, here, the reduction of bleed time in a subject. Examples of effective amounts typically range from about 0.5 g / 25 g body weight to about 0.0001 ng / 25 g body weight, and preferably about 5 mg / 25 g body to about 1 ng / 25 g body weight. Yet another embodiment of the present invention is directed to methods of reducing bleed time in a subject. The methods comprise activating the cholinergic anti-inflammatory pathway by directly stimulating the vagus nerve. As used herein, direct stimulation of the vagus nerve includes processes which involve direct contact with the vagus nerve or an organ served by the vagus nerve. One example of such a process, is electrical stimulation of the vagus nerve. Direct stimulation of the vagus nerve releases acetylcholine which results in the reduction of bleed time in the brain or in peripheral organs served by the vagus nerve. The vagus nerve enervates principal organs including, the pharynx, the larynx, the esophagus, the heart, the
lungs, the stomach, the pancreas, the spleen, the kidneys, the adrenal glands, the small and large intestine, the colon, and the liver. The vagus nerve can be stimulated by stimulating the entire vagus nerve (i.e., both the afferent and efferent nerves), or by isolating efferent nerves and stimulating them directly. The latter method can be accomplished by separating the afferent from the efferent fibers in an area of the nerve where both types of fibers are present. Alternatively, the efferent fiber is stimulated where no afferent fibers are present, for example close to the target organ served by the efferent fibers. The efferent fibers can also be stimulated by stimulating the target organ directly, e.g., electrically, thus stimulating the efferent fibers that serve that organ, hi other embodiments, the ganglion or postganglionic neurons of the vagus nerve can be stimulated. The vagus nerve can also be cut and the distal end can be stimulated, thus only stimulating efferent vagus nerve fibers. The vagus nerve can be directly stimulated by numerous methods. Nonlimiting examples include: mechanical means such as a needle, ultrasound, or vibration; electromagnetic radiation such as infrared, visible or ultraviolet light and electromagnetic fields; heat, or another energy source. Mechanical stimulation can also be carried out by carotid massage, oculocardiac reflex, dive reflex and valsalva maneuver. The efferent vagal nerve fibers can also be stimulated by electromagnetic radiation such as infrared, visible or ultraviolet light; heat, or any other energy source. hi preferred embodiments, the vagus nerve is directly stimulated electrically, using for example a commercial vagus nerve stimulator such as the Cyberonics NCP.RTM., or an electric probe. The amount of stimulation useful to reduce bleed time can be determined by the sldlled artisan without undue experimentation.
Examples of effective amounts of electrical stimulation required to reduce bleed time include, but are not limited to, a constant voltage of 0.1, 0.5, 1, 2, 3, 5, or 10 V, at a pulse width of 2 ms and signal frequency of 1-5 Hz, for 5 seconds, 10 seconds, 30 seconds, 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, or 1 hour. Alternatively, the electrical stimulation required to reduce bleed time include, but are
not limited to, a constant voltage of from about 0.01 to 1 V or from about 0.01 to 0.1 V or from about 0.01 to 0.05V; a signal current range from about 1 mA to about 100 mA, from about 1 mA to about 10 mA from about 1 mA to about 5 mA; a pulse width from about 0.1 to about 5 ms; signal frequencies of about 0.1 to about 30 Hz, or from about 1 to about 30 Hz, or from about 10 to about 30 Hz; a signal on-time from 1 to 120 seconds, or from about 10 to about 60 seconds, or from about 20 to about 40 seconds; signal off-time from 5 minutes, up to 2 hours, over 2 hours, over 4 hours, over 8 hours, over 12, hour, or from about 2 to about 48 hours, from about 4 to about 36 hours, from about 6 to about 36 hours from about 12 to about 36 hours, from about 16 to about 30 hours, from about 20 to about 28 hours. Alternatively, signal off-time can be undefined as one sldlled in the art will readily determine the desired time interval between two consecutive signals. Examples include, signal voltage to a range from about 0.01 V to about 1 V; pulse width to a range from about 0.1 ms to about 5 ms; signal frequency to a range from about 0.1 Hz to about 30 Hz; signal on-time from about 1 second to about 120 seconds. Signal off-time can be undefined. A signal voltage from about 0.01 V to about 0.1 V; pulse width to a range of about 0.1 ms to about 1 ms; signal frequency to a range from about 1 Hz to about 30 Hz; signal on-time to a range of from about 10 seconds to about 60 seconds; signal off-time to a range of over 2 hours. A signal voltage to a range from about 0.01 V to about 0.05 V; pulse width to a range from about 0.1 ms to about 0.5 ms; signal to a range from about 10 Hz to about 30 Hz; signal on-time to a range from about 20 seconds to about 40 seconds; signal off-time to a range from about 2 hours to about 24 hours. A signal current from about 1 mA to about 5 mA; pulse width to a range from about 0.1 ms to about 0.5 ms; signal to a range of about 10 Hz to about 30 Hz; signal on-time to a range from about 20 seconds to about 40 seconds; signal off-time can be undefined. In certain embodiments, electrical vagal nerve stimulation which is sufficient to activate the cholinergic anti-inflammatory pathway in a subject does not decrease the heart rate of the subject. In a preferred embodiment the vagus nerve is stimulated directly by means of
an implanted device. In another embodiment the cholinergic anti-inflammatory pathway is activated by administering an effective amount of acetylcholinesterase inhibitor to the subject. Examples of acetylcholinesterase inliibitors include: tacrine, donepezil, rivastigmine, galantamine, metrifonate, physostigmine, neostigmine, edrophonium, pyridostigmine, demacarium, and ambenonium. hi a still further embodiment the present invention is directed to reducing bleed time in a subject, the method comprising conditioning the subject to reduce bleed time by associating the activation of the cholinergic anti-inflammatory pathway with a sensory stimulus. Conditioning is a method of training an animal by which a perceptible neutral stimulus is temporarily associated with a physiological stimulus so that the animal will ultimately respond to the neutral stimulus as if it were the physiological stimulus. Pavlov, for instance, trained dogs to respond with salivation to the ringing of a bell following prior experiments where the dogs were prescribed a food stimulus (associated with salivation) simultaneously with a ringing bell stimulus. Thus, the present invention is directed to methods of conditioning a subject to reduce bleed time in the subject upon experiencing a sensory stimulus. The methods comprise the following steps: (a) activating the cholinergic anti-inflammatory pathway, and providing the sensory stimulus to the subject within a time period sufficient to create an association between the stimulus and the stimulation of the vagus nerve; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the bleed time to be reduced by the sensory stimulus alone. hi the conditioning step of these methods (step (a)), the CAP can be activated by any means previously discussed. The time interval between repetitions of the stimulus-activation procedures should also be short enough to optimize the reinforcement of the association. A common time interval is twice daily. The duration of the conditioning should also be sufficient to provide optimum
reinforcement of the association. A common duration is at least one week. Optimum time intervals and durations can be determined by the sldlled artisan without undue experimentation by standard methods -known in the art. The sensory stimulus can be from any of the five senses. Nonlimiting examples of suitable sensory stimuli are sounds such as a bell ring, a buzzer, and a musical passage; a touch such as a pin stick, a feather touch, and an electric shock; a taste, or the ingestion of a particular chemical, such as a sweet taste, a sour taste, a salty taste, and saccharine ingestion; and a visual image such as a still picture, a playing card, or a short video presentation. The methods of the present invention are ideally suited to therapeutically or prophylactically treat subjects suffering from or at risk from suffering from excessive bleeding due to injury, surgery, or bleeding disorders such as: Hemophilia A, Hemophilia B, von Willebrand Disease, Afibrinogenemia, Factor II Deficiency, Parahemophilia, Factor VII Deficiency, Stuart Prower Factor Deficiency, Hageman Factor Deficiency, Fibrin Stabilizing Factor Deficiency, Thombophilia, heridetary platelet function disorders (for example: Bernard-Soulier Syndrome, Glanzmann Thrombasthenia, Gray Platelet Syndrome, Scott Syndrome, May-Hegglin Anomaly, Alport Syndrome and Wiskott-Aldrich Syndrome), or acquired platelet function disorders (such as those caused by common drugs: blood thinners, antibiotics and anaesthetics and those caused by medical conditions such as: leukemia, heart bypass surgery and c-hronic kidney disease). The method is particularly suitable for subjects with bleeding disorders about to undergo, or undergoing surgery. The invention is illustrated by the following examples which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1 Reduction of bleed time in mouse model (male BALB/c mice) with electrical stimulation of the vagus nerve.
The mice were divided into two groups, hi both groups the mice necks were dissected down to the musculature and the left vagus nerves were isolated. In the first group a 1 volt electric current was passed through the vagus nerve for 20 minutes. In the second group, the control group, the vagus nerve was isolated only, and the group was untreated for 20 minutes. The mice tails from both groups were warmed in 37°C saline for five minutes. The tails were then cut 2 mm from the tip, and the tail blood was collected in a 37°C saline solution. The results of the experiment are presented in Figure 1. Electrical stimulation of the vagus nerve significantly reduced bleed time in the mice compared with the control group, thus demonstrating that stimulation of the vagus nerve decreases peripheral bleed time in a subject.
Example 2 Reduction in bleed time in mouse model (male BALB/c mice) with electrical stimulation of the vagus nerve. The mice were divided into two groups. In both groups the mice necks were dissected down to the musculature. The mice tails from both groups were warmed in 37°C saline for five minutes. hi both groups the left vagus nerves were isolated. In the first group a 1 volt electric current was passed through the vagus nerve for 30 seconds. The second group, the control group, was untreated for 30 seconds. The tails were then cut 2 mm from the tip, and the tail blood was collected in a 37°C saline solution. The results of this experiment are presented in Figure 2. Two parameters in this example were changed from Example 1, firstly the duration of stimulation was decreased from 20 minutes to 30 seconds and secondly the mice tails were prewarmed prior to vagus nerve stimulation. The purpose of prewarming the mice tails prior to vagus nerve stimulation was to minimize the delay between stimulation and transection. This reduction in the delay between stimulation and transection
resulted in a reduction in bleed time comparable with that shown in Example 1 where the mice tails were pre-warmed between the electrical stimulation and transection steps.
Example 3 Reduction of bleed time in mouse model (male Balb/c mice) with administration of nicotine.
The mice were weighed, and ketamine (100 mg/kg) and xylazine (10 mg/kg) was administered to each mouse. The mice were then divided into two groups. After 20 minutes group one was injected with nicotine (0.3 mg/kg) and the second group, the control group was injected with saline. The nicotine solution was taken from a 162 mg/ml stock solution and diluted 1 : 10 in ethanol and then further diluted 1 :250 in phosphate buffer saline (PBS), bringing the final solution to 0.0648 μg/μl; 115 μl/25 g mouse was injected into the mice. After five minutes the two groups were injected with a saline solution. After 20 minutes the mice tails from the two groups of mice were warmed by stirring in 37°C water. The tails were then cut 2 mm from the tip with a fresh scalpel. The tails were immediately immersed in a fluorescent activated sorting (FACS) tube which contained 3 ml pre-warmed saline. The tubes were held in a beaker of 37°C water which was continuously stirred. The tails remained near the bottom of the tube the entire bleeding period. The bleeding time was counted using a stopwatch. The mice were then euthanized by CO2 via a cardiac puncture with a heparinized needle. Administration of nicotine to the mice significantly reduced the bleed time, thus establishing that the activation of the cholinergic anti-inflammatory pathway by cholinergic agonists reduces peripheral bleed time in the subject. The results of this experiment are presented in Figure 3.
Example 4 Reduction of bleed time in mouse model (Male Balb/c mice) by cholinergic agonists
Male Balb/c mice (around 25 g) were injected (intraperitoneally (?□?)) with cholinergic agonist GTS-21 (4mg/kg in 125 μL PBS) or PBS (vehicle control, 125 μL). 1 hour later, mice were anesthetized with ketamine/xylazine (100 mg/kg / 10 mg/kg, intraperitoneally ). After immersing tails in 37 °C saline for 5 minutes to normalize vasodilatory state, 2 mm of tail was amputated with a scalpel, and returned to the saline bath (modified from Nagashima et al, Journal of Clinical Investigation (109) 101-110, (2002); Snyder et al, Nature Medicine (5), 64-70,
(1999). Total bleeding time was recorded; bleeding was considered to have stopped when no signs of bleeding were observed for 30 seconds. Once bleeding stopped, animals were euthanized by CO2 asphyxiation. Data were recorded in seconds, and are presented as mean +/- Standard Error (SE). Student's t-test was used for statistical analysis. The results are shown in Figure 4. Administration of GTS-21 to the mice significantly reduced the bleed time, thus establishing that the activation of the cholinergic anti-inflammatory pathway by cholinergic agonists reduces peripheral bleed time in the subject.
Example 5 Coagulation cascade measurements Male Balb/c mice (around 25g) were subjected to either left vagus nerve isolation only (sham surgery) or left vagus nerve electrical stimulation (1 Volt, 2 ms pulse width, 1 Hz) for 30 seconds. Immediately following stimulation, animals were euthanized, and blood was obtained by cardiac puncture and analyzed with a Hemochron JR whole blood microcoagulation system (International Technidyne Corp, Edison NJ). Each specific test cuvette: Prothrombin Time (PT), Activated
Partial Thromboplastin Time (APTT), Activated clotting time (ACT) is a self-contained disposable test chamber preloaded with a dried preparation of chemical reagents, stabilizers and buffers. The test cuvette was loaded with 50 μl of
fresh whole blood. After mixing with cuvette reagents, the sample was monitored for clot formation until the clot endpoint value was achieved. Data are presented as mean +/- Standard Error of the Mean (SEM), and were analyzed by Student's t-test. The results are shown in Figures 5-7. Figures 5-7 demonstrate that the coagulation cascade is not significantly affected by vagus nerve stimulation.
Example 6 Inhibition of bleed time in conscious mice by cholinergic agonists
Animals were injected (intraperitoneally) with cholinergic agonist nicotine (0.3 mg/kg in 125 μL PBS ; n=7) or PBS (vehicle control, 125 μL; n=4). lhour later, mice were placed in a restraint device, and the tails immersed in 37 °C water for 5 minutes. 20 mm of tail was amputated with a scalpel, and the truncated tail was placed in 37 °C saline. Total bleeding time was measured with a stop watch. Timing was stopped when no visual evidence of bleeding was noted, and no re-bleeding occurred for 30 seconds. Data were recorded in seconds, and are presented as mean +/- SE. Student's t-test was used for statistical analysis. The results can be seen in Figure 8. Administration of nicotine to the mice significantly reduced the bleed time, thus establishing that the activation of the cholinergic anti-inflammatory pathway by cholinergic agonists reduces peripheral bleed time in the conscious subject.
Example 7 Effect of administration of alpha-7 antagonist MLA on reduction of bleed time prior to administration of nicotine
Male Balb/c mice (around 25g) were divided into three groups: A, B and C. Groups A and C were injected with the alpha-7 antagonist methyllycaconitine, (MLA; 4mg/kg, IP, in 200μL PBS), group B was injected with PBS (vehicle control,
125μl). 15 minutes later, Group A was injected with PBS (vehicle control, 125μl)and groups B and C were injected with, nicotine (0.3mg/kg in 125 μL PBS).
30 minutes later, mice were anesthetized (ketamine [lOOmg/kg, IP] and xylazine [lOmg/kg, IP]). After immersing tails in 37°C saline for 5 minutes to normalize vasodilatory state, 2 mm of tail was amputated with a scalpel, and returned to the saline bath (modified from Nagashima et al, Journal of Clinical Investigation (109) 101-110, (2002); Snyder et al, Nature Medicine (5), 64-70, (1999). Total bleeding time was recorded; bleeding was considered to have stopped when no signs of bleeding were observed for 30 seconds. Once bleeding stopped, animals were euthanized by CO2 asphyxiation. Data were recorded in seconds, and are presented as mean +/- SE. Student's t-test was used for statistical analysis. The results are shown in Figure 9 which shows a reduction in bleed time following administration of nicotine. MLA inhibited nicotine induced reduction of bleed time, suggesting that nicotine reduced bleed time via alpha-7 cholinergic receptor subunit.
Claims
1. A method of reducing bleed time in a subj ect in need of such treatment, the method comprising activating the cholinergic anti-inflammatory pathway.
2. The method of claim 1 wherein the subject is a human.
3. The method of Claim 1 wherein the cholinergic anti-inflammatory pathway is activated by stimulating the vagus nerve.
4. The method of Claim 3 wherein the cholinergic anti-inflammatory pathway is activated by stimulating the vagus nerve in the brain.
5. The method of Claim 4 wherein the vagus nerve is indirectly stimulated by administering an effective amount of a muscarinic agonist to the subject.
6. The method of Claim 5 wherein the muscarinic agonist is muscarine, McN-A- 343, or MT-3.
7. The method of Claim 5 wherein the muscarinic agonist is an aromatic amidmohydrazone.
8. The method of Claim 7 wherein the muscarinic agonist is N,N'-bis(3,5- diacetylphenyl) decanediamide tetrakis (amidmohydrazone) tetrahydrochloride (CM-1493).
9. The method of Claim 7 wherein the muscarinic agonist is a compound having the structural formula I:
wherein: X2 is NH2(CMI)-? H-N=CH-, NH2(CNH)-Mi-N=CCH3- or H-; Xl5 X*! and X*2 independently are NH2(CNH)-MI-N=CH- or NH2(CNH)-NH-N=CCH3-; Z is -?MI(CO)NH-, -(C6H4)-, -(C5NH3)- or -A-(CH2)n-A-; n is 2-10; and A independently is -NH(CO)-, -NH(CO)NH-, -NH- or -O-; or a pharmaceutically acceptable salt thereof.
10. The method of claim 7 wherein the muscarinic agonist is a compound having the structural formula H:
π wherein: Xi, X2 and X3 independently are NH2(C?MI)-NH-N=CH- or NH2(CNH)-NH-N=CCH3-; X'ι, X'2 and X'3 independently are H-, NH2(CNH)-NH-N=CH- or NH2(CNH)-NH-N=CCH3-; Z is (C6H3) and m m2, and m3 are 0; or Z is N and independently m2 and m3 are 2-6; A is -NH(CO)-, -NH(CO)NH-, -NH- or -O-; or a pharmaceutically acceptable salt thereof.
11. The method of Claim 5 wherein the muscarinic agonist is administered directly to the brain of the subject.
12. The method of Claim 5 wherein the muscarinic agonist can permeate the brain of the subject.
13. The method of Claim 1 wherein the cholinergic anti-inflammatory pathway is activated by administering an effective amount of a cholinergic agonist to the subject.
14. The method of Claim 13 wherein the cholinergic agonist is acetylcholine, nicotine, muscarine, carbachol, galantamine, arecoline, cevimeline, or levamisole.
15. The method of Claim 13 wherein the cholinergic agonist is nicotine.
16. The method of Claim 13 wherein the cholinergic agonist is selective for an 7 nicotinic receptor.
17. The method of Claim 16 wherein the α7 selective nicotinic agonist is a compound of structural formula HI:
in wherein: R is hydrogen or methyl; and n is 0 or 1 ; or a pharmaceutically acceptable salt thereof.
18. The method of Claim 17 wherein the α7 selective nicotinic agonist is (-)- spiro-[l-azabicyclo[2.2.2]octane-3,5'-octane-3,5'oxazolidin-2'-one.
19. The method of Claim 16 wherein the α7 selective nicotinic agonist is a compound of structural formula IV:
IV
wherein: m is 1 or 2; n is O or 1; Y is CH, N, orNO; X is oxygen or sulfur; W is oxygen, H2, or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G, and D is nitrogen but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or C, to C4 alkyl; R2, R3, and R4 are independently hydrogen, halogen, Cι-C4 allcyl, C2- C4 allcenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OCrC4 allcyl, CO2R1 > - CN, -NO2, -NR5 R6, -CF3 or -OSO2CF3; or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substitutents: independently hydrogen, halogen, CrC4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OCrC4 allcyl, CO.R1, -CN, -NO2, -NR5R6, -CF3 or -OSO2CF3; R5 and R6 are independently hydrogen, CrC4 alkyl, C(O)R7, C(O)NHR8, C(O)OR9, SO2R10 or may together be (CH^QiCH^; where Q is O, S, NRn, or a bond; j is 2 to 7; k is 0 to 2; and R7, R8, R9, R10, and R11 are independently CrC4, allcyl, aryl, or heteroaryl; an enantiomer thereof; or a pharmaceutically acceptable salt thereof.
20. The method of Claim 19 wherein the α7 selective nicotinic agonist is (R)-(-)- 5'-phenylspiro[l-azabicyclo[2.2.2]octane-3,2Octane-3,2'(3'H)-furo[2,3- b]pyridine].
21. The method of Claim 16 wherein the α7 selective nicotinic agonist is a compound of structural foπnula V:
V wherein: R1 is hydrogen or CrC4 alkyl; R6 and R7 are independently absent, hydrogen or CrC4 allcyl; and R2 is:
or
wherein: R3, R4 and R5 are independently hydrogen, CrC4 alkyl optionally substituted with N,N-dialkylamino having 1 to 4 carbons in each of the alkyls, C C6 alkoxy optionally substituted with N, N-dialkylamino having 1 to 4 carbons in each of the alkyls, carboalkoxy having 1 to 4 carbons in the alkoxy, amino, amido having 1 to 4 carbons in the acyl, cyano, and N,N-dialkylamino having 1 to 4 carbons in each of the alkyls, halo, hydroxyl, or nitro.
22. The method of Claim 21 wherein the α7 selective nicotinic agonist is trans-3- cinnamylidene anabaseine, trans-3-(2-methoxy-cinnamylidene)anabaseine or trans-3-(4-methoxycinnamylidene anabaseine, 3-(4-hydroxy-2- methoxybenzylidene)anabaseine or 3-(2,4-dimethoxybenzyldine)anabaseine (GTS-21).
23. The method of Claim 16 wherein the α7 selective nicotinic agonist is a compound of structural formula VI:
VI wherein: X is O or S; R is H, OR1, NHC(O)R1, or a halogen; and R1 is a CrC4 allcyl; or a pharmaceutically acceptable salt thereof.
24. The method of Claim 16 wherein the α7 selective nicotinic agonist is (1-aza-bicyclo [2.2.2] oct-3-yl)-carbamic acid l-(2-fluorophenyl)-ethyl ester.
25. The method of Claim 16 wherein the 7 selective nicotinic agonist is cocaine methiodide.
26. The method of Claim 16 wherein the α7 selective nicotinic agonist is choline.
27. The method of Claim 3 wherein the vagus nerve is indirectly stimulated.
28. The method of Claim 27 wherein the vagus nerve is indirectly stimulated with a transdermal or trans-esophogeal device.
29. The method of Claim 3 wherein the vagus nerve is directly stimulated.
30. The method of Claim 29 wherein the vagus nerve is stimulated electrically.
31. The method of Claim 29 wherein the efferent vagus nerve is stimulated.
32. The method of Claim 31 wherein the efferent vagus nerve is stimulated electrically.
33. The method of Claim 29 wherein the vagus nerve is directly stimulated with an implanted device.
34. The method of Claim 1 wherein the cholinergic anti-inflammatory pathway is activated by administering an acetylcholinesterase inhibitor to the subject.
35. The method of Claim 1 wherein the subject suffers from a condition of hemophilia.
36. The method of Claim 1 wherein the subject is suffering from a clotting disorder other than hemophilia.
37. The method of Claim 1 wherein the subject is suffering bleeding caused by a wound.
38. The method of Claim 1 wherein the subject is undergoing surgery.
39. The method of Claim 1 wherein the cholinergic anti-inflammatory pathway is stimulated prior to surgery.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55609604P | 2004-03-25 | 2004-03-25 | |
PCT/US2005/009954 WO2005092308A2 (en) | 2004-03-25 | 2005-03-24 | Neural tourniquet |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1734941A2 true EP1734941A2 (en) | 2006-12-27 |
Family
ID=34971547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05755668A Withdrawn EP1734941A2 (en) | 2004-03-25 | 2005-03-24 | Neural tourniquet |
Country Status (6)
Country | Link |
---|---|
US (1) | US8729129B2 (en) |
EP (1) | EP1734941A2 (en) |
JP (1) | JP2007530586A (en) |
AU (1) | AU2005225458B2 (en) |
CA (1) | CA2560756A1 (en) |
WO (1) | WO2005092308A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
AU2005323463B2 (en) | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
US8862243B2 (en) | 2005-07-25 | 2014-10-14 | Rainbow Medical Ltd. | Electrical stimulation of blood vessels |
EP2801359A3 (en) * | 2006-05-08 | 2015-05-06 | Arturo Solis Herrera | The use of nicotine for the treatment of sepsis in humans caused by antibiotic |
WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
US8233976B2 (en) | 2007-12-05 | 2012-07-31 | The Invention Science Fund I, Llc | System for transdermal chemical modulation of neural activity |
US8989858B2 (en) * | 2007-12-05 | 2015-03-24 | The Invention Science Fund I, Llc | Implant system for chemical modulation of neural activity |
US8538535B2 (en) | 2010-08-05 | 2013-09-17 | Rainbow Medical Ltd. | Enhancing perfusion by contraction |
US9005106B2 (en) | 2008-01-31 | 2015-04-14 | Enopace Biomedical Ltd | Intra-aortic electrical counterpulsation |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
CN102215909B (en) | 2008-11-18 | 2014-09-10 | 赛博恩特医疗器械公司 | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
US8612002B2 (en) | 2009-12-23 | 2013-12-17 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
CN103619405B (en) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | The individual pulse being used for the treatment of the cholinergic anti-inflammatory pathway of chronic inflammatory disease activates |
WO2013035092A2 (en) | 2011-09-09 | 2013-03-14 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
WO2015068167A2 (en) | 2013-11-06 | 2015-05-14 | Enopace Biomedical Ltd. | Wireless endovascular stent-based electrodes |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
CA3088403A1 (en) | 2018-01-30 | 2019-08-08 | Apex Neuro Holdings, Inc. | Devices and methods for treatment of anxiety and related disorders via delivery of mechanical stimulation to nerve, mechanoreceptor, and cell targets |
US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
US11433235B2 (en) | 2018-04-20 | 2022-09-06 | The Feinstein Institutes For Medical Research | Systems and methods for delivering non-invasive neuromodulation to reduce the effects of shock and traumatic brain injury in animals and humans and to prolong life |
CN113711623A (en) | 2018-09-24 | 2021-11-26 | Nesos公司 | Neural stimulation of the ear for treating a patient's disease, and related systems and methods |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
WO2023224636A1 (en) | 2022-05-20 | 2023-11-23 | Spark Biomedical, Inc. | Devices for treating stress and improving alertness using electrical stimulation |
Family Cites Families (342)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2164121A (en) | 1938-05-04 | 1939-06-27 | Pescador Hector | Electric hearing apparatus for the deaf |
US3363623A (en) * | 1965-07-28 | 1968-01-16 | Charles F. Atwell | Hand-held double-acting nerve reflex massager |
FR2315274A1 (en) | 1975-06-27 | 1977-01-21 | Parcor | NEW DERIVATIVES OF THIENO (2,3-C) PYRIDINE, THEIR PREPARATION AND THEIR APPLICATIONS |
US4073296A (en) * | 1976-01-02 | 1978-02-14 | Mccall Francis J | Apparatus for acupressure treatment |
US4098277A (en) | 1977-01-28 | 1978-07-04 | Sherwin Mendell | Fitted, integrally molded device for stimulating auricular acupuncture points and method of making the device |
US4503863A (en) * | 1979-06-29 | 1985-03-12 | Katims Jefferson J | Method and apparatus for transcutaneous electrical stimulation |
US4305402A (en) | 1979-06-29 | 1981-12-15 | Katims Jefferson J | Method for transcutaneous electrical stimulation |
US5025807A (en) | 1983-09-14 | 1991-06-25 | Jacob Zabara | Neurocybernetic prosthesis |
US4867164A (en) | 1983-09-14 | 1989-09-19 | Jacob Zabara | Neurocybernetic prosthesis |
US4702254A (en) | 1983-09-14 | 1987-10-27 | Jacob Zabara | Neurocybernetic prosthesis |
US4590946A (en) | 1984-06-14 | 1986-05-27 | Biomed Concepts, Inc. | Surgically implantable electrode for nerve bundles |
US4573481A (en) * | 1984-06-25 | 1986-03-04 | Huntington Institute Of Applied Research | Implantable electrode array |
US4649936A (en) * | 1984-10-11 | 1987-03-17 | Case Western Reserve University | Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking |
US4632095A (en) | 1984-11-05 | 1986-12-30 | Tamiko Inc. | Pressure-point attachment for use with electrical hand-held massagers |
US4929734A (en) | 1987-03-31 | 1990-05-29 | Warner-Lambert Company | Tetrahydropyridine oxime compounds |
US4840793A (en) | 1987-06-11 | 1989-06-20 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
US4935234A (en) | 1987-06-11 | 1990-06-19 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
US5019648A (en) | 1987-07-06 | 1991-05-28 | Dana-Farber Cancer Institute | Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein |
DE3736664A1 (en) | 1987-10-29 | 1989-05-11 | Boehringer Ingelheim Kg | TETRAHYDRO-FURO- AND -THIENO (2,3-C) PYRIDINE, THEIR USE AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF |
US5038781A (en) | 1988-01-21 | 1991-08-13 | Hassan Hamedi | Multi-electrode neurological stimulation apparatus |
US5049659A (en) | 1988-02-09 | 1991-09-17 | Dana Farber Cancer Institute | Proteins which induce immunological effector cell activation and chemattraction |
US4991578A (en) * | 1989-04-04 | 1991-02-12 | Siemens-Pacesetter, Inc. | Method and system for implanting self-anchoring epicardial defibrillation electrodes |
US5106853A (en) * | 1989-05-15 | 1992-04-21 | Merck Sharp & Dohme, Ltd. | Oxadiazole and its salts, their use in treating dementia |
US4979511A (en) | 1989-11-03 | 1990-12-25 | Cyberonics, Inc. | Strain relief tether for implantable electrode |
US5186170A (en) * | 1989-11-13 | 1993-02-16 | Cyberonics, Inc. | Simultaneous radio frequency and magnetic field microprocessor reset circuit |
US5179950A (en) * | 1989-11-13 | 1993-01-19 | Cyberonics, Inc. | Implanted apparatus having micro processor controlled current and voltage sources with reduced voltage levels when not providing stimulation |
US5235980A (en) | 1989-11-13 | 1993-08-17 | Cyberonics, Inc. | Implanted apparatus disabling switching regulator operation to allow radio frequency signal reception |
US5154172A (en) | 1989-11-13 | 1992-10-13 | Cyberonics, Inc. | Constant current sources with programmable voltage source |
US5726017A (en) * | 1990-06-11 | 1998-03-10 | Nexstar Pharmaceuticals, Inc. | High affinity HIV-1 gag nucleic acid ligands |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5496938A (en) * | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
US5472841A (en) | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
US6124449A (en) | 1990-06-11 | 2000-09-26 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
US5712375A (en) * | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
DE69128350T2 (en) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | NUCLEIC ACID LIGANDS |
US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
US5705337A (en) * | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
US6147204A (en) | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US6127119A (en) | 1990-06-11 | 2000-10-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
US6083696A (en) | 1990-06-11 | 2000-07-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands exponential enrichment: blended selex |
US5073560A (en) | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
US5111815A (en) | 1990-10-15 | 1992-05-12 | Cardiac Pacemakers, Inc. | Method and apparatus for cardioverter/pacer utilizing neurosensing |
US5263480A (en) | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5269303A (en) | 1991-02-22 | 1993-12-14 | Cyberonics, Inc. | Treatment of dementia by nerve stimulation |
US5251634A (en) | 1991-05-03 | 1993-10-12 | Cyberonics, Inc. | Helical nerve electrode |
US5299569A (en) * | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US5215086A (en) | 1991-05-03 | 1993-06-01 | Cyberonics, Inc. | Therapeutic treatment of migraine symptoms by stimulation |
US5335657A (en) | 1991-05-03 | 1994-08-09 | Cyberonics, Inc. | Therapeutic treatment of sleep disorder by nerve stimulation |
US6028186A (en) * | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
US5205285A (en) * | 1991-06-14 | 1993-04-27 | Cyberonics, Inc. | Voice suppression of vagal stimulation |
WO1993001862A1 (en) | 1991-07-22 | 1993-02-04 | Cyberonics, Inc. | Treatment of respiratory disorders by nerve stimulation |
US5222494A (en) | 1991-07-31 | 1993-06-29 | Cyberonics, Inc. | Implantable tissue stimulator output stabilization system |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US5175166A (en) | 1991-08-27 | 1992-12-29 | The University Of Toledo | Muscarinic agonists |
US5215089A (en) | 1991-10-21 | 1993-06-01 | Cyberonics, Inc. | Electrode assembly for nerve stimulation |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5237991A (en) | 1991-11-19 | 1993-08-24 | Cyberonics, Inc. | Implantable medical device with dummy load for pre-implant testing in sterile package and facilitating electrical lead connection |
US5203326A (en) * | 1991-12-18 | 1993-04-20 | Telectronics Pacing Systems, Inc. | Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy |
US5330507A (en) | 1992-04-24 | 1994-07-19 | Medtronic, Inc. | Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias |
US5330515A (en) | 1992-06-17 | 1994-07-19 | Cyberonics, Inc. | Treatment of pain by vagal afferent stimulation |
JP3034953B2 (en) * | 1992-08-31 | 2000-04-17 | ユニバーシティー オブ フロリダ リサーチ ファンデーション,インコーポレーテッド | Anabaseine derivatives useful for the treatment of degenerative diseases of the nervous system |
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
DE59410125D1 (en) * | 1993-02-10 | 2002-07-04 | Siemens Ag | DEVICE FOR PAIN THERAPY AND / OR INFLUENCING THE VEGETATIVE NERVOUS SYSTEM |
US5344438A (en) | 1993-04-16 | 1994-09-06 | Medtronic, Inc. | Cuff electrode |
AU698101B2 (en) | 1993-06-01 | 1998-10-22 | Cortex Pharmaceuticals, Inc. | Alkaline and acid phosphatase inhibitors in treatment of neurological disorders |
US5594106A (en) | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
JP3269125B2 (en) * | 1994-01-28 | 2002-03-25 | 東レ株式会社 | Atopic dermatitis drug |
ES2157326T3 (en) | 1994-04-22 | 2001-08-16 | Sanquin Bloedvoorziening | SYSTEM FOR THE TREATMENT OF ANOMALIES IN THE CASCADA DE COAGULACION SANGUINEA. |
US5458625A (en) | 1994-05-04 | 1995-10-17 | Kendall; Donald E. | Transcutaneous nerve stimulation device and method for using same |
US6017891A (en) * | 1994-05-06 | 2000-01-25 | Baxter Aktiengesellschaft | Stable preparation for the treatment of blood coagulation disorders |
US6405732B1 (en) | 1994-06-24 | 2002-06-18 | Curon Medical, Inc. | Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors |
KR100366331B1 (en) | 1994-08-24 | 2003-04-10 | 아스트라제네카 악티에볼라그 | Spiro-azabicyclic Compounds Useful for Treatment |
US5531778A (en) | 1994-09-20 | 1996-07-02 | Cyberonics, Inc. | Circumneural electrode assembly |
US5540734A (en) | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5571150A (en) * | 1994-12-19 | 1996-11-05 | Cyberonics, Inc. | Treatment of patients in coma by nerve stimulation |
US5487756A (en) * | 1994-12-23 | 1996-01-30 | Simon Fraser University | Implantable cuff having improved closure |
US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
US5540730A (en) | 1995-06-06 | 1996-07-30 | Cyberonics, Inc. | Treatment of motility disorders by nerve stimulation |
US5707400A (en) * | 1995-09-19 | 1998-01-13 | Cyberonics, Inc. | Treating refractory hypertension by nerve stimulation |
US5700282A (en) | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
WO1997014473A1 (en) * | 1995-10-18 | 1997-04-24 | Novartis Ag | Thermopile powered transdermal drug delivery device |
US5611350A (en) * | 1996-02-08 | 1997-03-18 | John; Michael S. | Method and apparatus for facilitating recovery of patients in deep coma |
US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US5651378A (en) | 1996-02-20 | 1997-07-29 | Cardiothoracic Systems, Inc. | Method of using vagal nerve stimulation in surgery |
US6051017A (en) * | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
US5913876A (en) * | 1996-02-20 | 1999-06-22 | Cardiothoracic Systems, Inc. | Method and apparatus for using vagus nerve stimulation in surgery |
US5618818A (en) * | 1996-03-20 | 1997-04-08 | The University Of Toledo | Muscarinic agonist compounds |
DK0796623T3 (en) | 1996-03-20 | 2005-08-01 | Baxter Ag | Pharmaceutical composition for the treatment of blood clotting disorders |
EP0796634B1 (en) | 1996-03-21 | 2005-11-16 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Implantable stimulation electrode |
US5690681A (en) | 1996-03-29 | 1997-11-25 | Purdue Research Foundation | Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation |
US5726179A (en) * | 1996-04-01 | 1998-03-10 | The University Of Toledo | Muscarinic agonists |
US6166048A (en) | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US6735471B2 (en) | 1996-04-30 | 2004-05-11 | Medtronic, Inc. | Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure |
US6532388B1 (en) * | 1996-04-30 | 2003-03-11 | Medtronic, Inc. | Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure |
US7225019B2 (en) | 1996-04-30 | 2007-05-29 | Medtronic, Inc. | Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure |
US6006134A (en) | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US6628987B1 (en) | 2000-09-26 | 2003-09-30 | Medtronic, Inc. | Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia |
US6904318B2 (en) | 2000-09-26 | 2005-06-07 | Medtronic, Inc. | Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure |
US6449507B1 (en) * | 1996-04-30 | 2002-09-10 | Medtronic, Inc. | Method and system for nerve stimulation prior to and during a medical procedure |
USRE38705E1 (en) * | 1996-04-30 | 2005-02-22 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US20040199209A1 (en) | 2003-04-07 | 2004-10-07 | Hill Michael R.S. | Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure |
US7269457B2 (en) | 1996-04-30 | 2007-09-11 | Medtronic, Inc. | Method and system for vagal nerve stimulation with multi-site cardiac pacing |
US5853005A (en) | 1996-05-02 | 1998-12-29 | The United States Of America As Represented By The Secretary Of The Army | Acoustic monitoring system |
AU3304997A (en) * | 1996-05-31 | 1998-01-05 | Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
US5792210A (en) | 1996-06-10 | 1998-08-11 | Environmental Behavior Modification Inc. | Electrical tongue stimulator and method for addiction treatment |
JPH1094613A (en) | 1996-08-02 | 1998-04-14 | Mieko Sato | Appetite adjusting implement |
US5718912A (en) * | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
CA2271693C (en) | 1996-11-15 | 2009-01-20 | The Picower Institute For Medical Research | Guanylhydrazones useful for treating diseases associated with t cell activation |
US5788656A (en) | 1997-02-28 | 1998-08-04 | Mino; Alfonso Di | Electronic stimulation system for treating tinnitus disorders |
US5919216A (en) | 1997-06-16 | 1999-07-06 | Medtronic, Inc. | System and method for enhancement of glucose production by stimulation of pancreatic beta cells |
AR013184A1 (en) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | SPYROZOBICYCLIC HETERO CYCLIC AMINES, PHARMACEUTICAL COMPOSITION, USE OF SUCH AMINES TO PREPARE MEDICINES AND METHOD OF TREATMENT OR PROPHYLAXIS |
US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
US6011005A (en) | 1997-09-18 | 2000-01-04 | The Picower Institute For Medical Research | Prevention of pregnancy miscarriages |
US6141590A (en) | 1997-09-25 | 2000-10-31 | Medtronic, Inc. | System and method for respiration-modulated pacing |
US6528529B1 (en) * | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6018682A (en) * | 1998-04-30 | 2000-01-25 | Medtronic, Inc. | Implantable seizure warning system |
US5928272A (en) | 1998-05-02 | 1999-07-27 | Cyberonics, Inc. | Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity |
US6002964A (en) | 1998-07-15 | 1999-12-14 | Feler; Claudio A. | Epidural nerve root stimulation |
US7242984B2 (en) | 1998-08-05 | 2007-07-10 | Neurovista Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US7599736B2 (en) * | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US6505074B2 (en) | 1998-10-26 | 2003-01-07 | Birinder R. Boveja | Method and apparatus for electrical stimulation adjunct (add-on) treatment of urinary incontinence and urological disorders using an external stimulator |
US20030212440A1 (en) | 2002-05-09 | 2003-11-13 | Boveja Birinder R. | Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system |
US6269270B1 (en) | 1998-10-26 | 2001-07-31 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of Dementia and Alzheimer's disease utilizing an implantable lead and external stimulator |
US6668191B1 (en) | 1998-10-26 | 2003-12-23 | Birinder R. Boveja | Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator |
US6356788B2 (en) * | 1998-10-26 | 2002-03-12 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US6205359B1 (en) * | 1998-10-26 | 2001-03-20 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US6208902B1 (en) * | 1998-10-26 | 2001-03-27 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy for pain syndromes utilizing an implantable lead and an external stimulator |
US6611715B1 (en) | 1998-10-26 | 2003-08-26 | Birinder R. Boveja | Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator |
US7076307B2 (en) | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
US20050137644A1 (en) | 1998-10-26 | 2005-06-23 | Boveja Birinder R. | Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders |
US6366814B1 (en) | 1998-10-26 | 2002-04-02 | Birinder R. Boveja | External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders |
US6615081B1 (en) | 1998-10-26 | 2003-09-02 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator |
US6564102B1 (en) | 1998-10-26 | 2003-05-13 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator |
US5994330A (en) | 1998-11-09 | 1999-11-30 | El Khoury; Georges F. | Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions |
FR2786770B1 (en) | 1998-12-04 | 2001-01-19 | Synthelabo | NONANE 1,4-DIAZABICYCLO [3.2.2.] DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US6376675B2 (en) | 1999-01-22 | 2002-04-23 | The University Of Toledo | Muscarinic receptor agonists |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US6341236B1 (en) * | 1999-04-30 | 2002-01-22 | Ivan Osorio | Vagal nerve stimulation techniques for treatment of epileptic seizures |
CA2376903A1 (en) | 1999-06-25 | 2001-01-04 | Emory University | Devices and methods for vagus nerve stimulation |
US6233488B1 (en) | 1999-06-25 | 2001-05-15 | Carl A. Hess | Spinal cord stimulation as a treatment for addiction to nicotine and other chemical substances |
US6587719B1 (en) * | 1999-07-01 | 2003-07-01 | Cyberonics, Inc. | Treatment of obesity by bilateral vagus nerve stimulation |
US6804558B2 (en) | 1999-07-07 | 2004-10-12 | Medtronic, Inc. | System and method of communicating between an implantable medical device and a remote computer system or health care provider |
US6171795B1 (en) * | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
US6210321B1 (en) | 1999-07-29 | 2001-04-03 | Adm Tronics Unlimited, Inc. | Electronic stimulation system for treating tinnitus disorders |
US6304775B1 (en) | 1999-09-22 | 2001-10-16 | Leonidas D. Iasemidis | Seizure warning and prediction |
US6636767B1 (en) | 1999-09-29 | 2003-10-21 | Restore Medical, Inc. | Implanatable stimulation device for snoring treatment |
US6473644B1 (en) | 1999-10-13 | 2002-10-29 | Cyberonics, Inc. | Method to enhance cardiac capillary growth in heart failure patients |
US20020026141A1 (en) * | 1999-11-04 | 2002-02-28 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
FR2803186B1 (en) | 2000-01-05 | 2002-08-09 | Guy Charvin | METHOD AND APPARATUS FOR COLLECTING HEARING MESSAGE POTENTIALS |
US6447443B1 (en) | 2001-01-13 | 2002-09-10 | Medtronic, Inc. | Method for organ positioning and stabilization |
US6885888B2 (en) * | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
US20060085046A1 (en) | 2000-01-20 | 2006-04-20 | Ali Rezai | Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system |
US6356787B1 (en) * | 2000-02-24 | 2002-03-12 | Electro Core Techniques, Llc | Method of treating facial blushing by electrical stimulation of the sympathetic nerve chain |
US6826428B1 (en) | 2000-04-11 | 2004-11-30 | The Board Of Regents Of The University Of Texas System | Gastrointestinal electrical stimulation |
JP2003530169A (en) | 2000-04-11 | 2003-10-14 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | Electrical stimulation of the gastrointestinal tract |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6511500B1 (en) * | 2000-06-06 | 2003-01-28 | Marc Mounir Rahme | Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects |
WO2002016357A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
US6487446B1 (en) * | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
US20020077675A1 (en) | 2000-09-26 | 2002-06-20 | Transneuronix, Inc. | Minimally invasive surgery placement of stimulation leads in mediastinal structures |
EP1324709B1 (en) | 2000-09-26 | 2006-07-12 | Medtronic, Inc. | Medical device for directing blood flow |
AU2002210378A1 (en) * | 2000-10-11 | 2002-04-22 | Ronald R. Riso | Nerve cuff electrode |
US7011638B2 (en) * | 2000-11-14 | 2006-03-14 | Science Medicus, Inc. | Device and procedure to treat cardiac atrial arrhythmias |
US6832114B1 (en) | 2000-11-21 | 2004-12-14 | Advanced Bionics Corporation | Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes |
US6633779B1 (en) | 2000-11-27 | 2003-10-14 | Science Medicus, Inc. | Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms |
JP2004514722A (en) | 2000-12-01 | 2004-05-20 | ニューロサーチ、アクティーゼルスカブ | 3-Substituted quinuclidine and methods of using same as nicotine antagonists |
US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
US6609025B2 (en) | 2001-01-02 | 2003-08-19 | Cyberonics, Inc. | Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation |
US7519421B2 (en) | 2001-01-16 | 2009-04-14 | Kenergy, Inc. | Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation |
WO2002057275A1 (en) | 2001-01-17 | 2002-07-25 | University Of Kentucky Research Foundation | Boron-containing nicotine analogs for use in the treatment of cns pathologies |
US6735475B1 (en) | 2001-01-30 | 2004-05-11 | Advanced Bionics Corporation | Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain |
US7167751B1 (en) * | 2001-03-01 | 2007-01-23 | Advanced Bionics Corporation | Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation |
US7069082B2 (en) | 2001-04-05 | 2006-06-27 | Med-El Elektromedizinische Gerate Gmbh | Pacemaker for bilateral vocal cord autoparalysis |
US7369897B2 (en) | 2001-04-19 | 2008-05-06 | Neuro And Cardiac Technologies, Llc | Method and system of remotely controlling electrical pulses provided to nerve tissue(s) by an implanted stimulator system for neuromodulation therapies |
US6684105B2 (en) | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US20050240229A1 (en) | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
US6928320B2 (en) | 2001-05-17 | 2005-08-09 | Medtronic, Inc. | Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated |
US7054692B1 (en) | 2001-06-22 | 2006-05-30 | Advanced Bionics Corporation | Fixation device for implantable microdevices |
US20060116736A1 (en) | 2001-07-23 | 2006-06-01 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity |
US20060167498A1 (en) | 2001-07-23 | 2006-07-27 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease |
US6622047B2 (en) | 2001-07-28 | 2003-09-16 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation |
US6622038B2 (en) | 2001-07-28 | 2003-09-16 | Cyberonics, Inc. | Treatment of movement disorders by near-diaphragmatic nerve stimulation |
US6622041B2 (en) | 2001-08-21 | 2003-09-16 | Cyberonics, Inc. | Treatment of congestive heart failure and autonomic cardiovascular drive disorders |
US6600956B2 (en) | 2001-08-21 | 2003-07-29 | Cyberonics, Inc. | Circumneural electrode assembly |
US6760626B1 (en) | 2001-08-29 | 2004-07-06 | Birinder R. Boveja | Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system |
US7054686B2 (en) | 2001-08-30 | 2006-05-30 | Biophan Technologies, Inc. | Pulsewidth electrical stimulation |
US7778703B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
US7734355B2 (en) | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US7885709B2 (en) | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
US7778711B2 (en) | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
US6934583B2 (en) | 2001-10-22 | 2005-08-23 | Pacesetter, Inc. | Implantable lead and method for stimulating the vagus nerve |
US6745079B2 (en) | 2001-11-07 | 2004-06-01 | Medtronic, Inc. | Electrical tissue stimulation apparatus and method |
US7155284B1 (en) | 2002-01-24 | 2006-12-26 | Advanced Bionics Corporation | Treatment of hypertension |
US6721603B2 (en) | 2002-01-25 | 2004-04-13 | Cyberonics, Inc. | Nerve stimulation as a treatment for pain |
EP1487494A2 (en) * | 2002-02-26 | 2004-12-22 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
US7689276B2 (en) * | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
US7937145B2 (en) | 2002-03-22 | 2011-05-03 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation employing frequency modulation |
US7465555B2 (en) | 2002-04-02 | 2008-12-16 | Becton, Dickinson And Company | Early detection of sepsis |
US6978787B1 (en) | 2002-04-03 | 2005-12-27 | Michael Broniatowski | Method and system for dynamic vocal fold closure with neuro-electrical stimulation |
US20030191404A1 (en) | 2002-04-08 | 2003-10-09 | Klein George J. | Method and apparatus for providing arrhythmia discrimination |
WO2003092796A1 (en) | 2002-05-03 | 2003-11-13 | Musc Foundation For Research Development | Method, apparatus and system for determining effects and optimizing parameters of vagus nerve stimulation |
US20070067004A1 (en) * | 2002-05-09 | 2007-03-22 | Boveja Birinder R | Methods and systems for modulating the vagus nerve (10th cranial nerve) to provide therapy for neurological, and neuropsychiatric disorders |
US20050216070A1 (en) | 2002-05-09 | 2005-09-29 | Boveja Birinder R | Method and system for providing therapy for migraine/chronic headache by providing electrical pulses to vagus nerve(s) |
US20060009815A1 (en) * | 2002-05-09 | 2006-01-12 | Boveja Birinder R | Method and system to provide therapy or alleviate symptoms of involuntary movement disorders by providing complex and/or rectangular electrical pulses to vagus nerve(s) |
US20050154426A1 (en) | 2002-05-09 | 2005-07-14 | Boveja Birinder R. | Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation |
US7191012B2 (en) * | 2003-05-11 | 2007-03-13 | Boveja Birinder R | Method and system for providing pulsed electrical stimulation to a craniel nerve of a patient to provide therapy for neurological and neuropsychiatric disorders |
US20050165458A1 (en) | 2002-05-09 | 2005-07-28 | Boveja Birinder R. | Method and system to provide therapy for depression using electroconvulsive therapy(ECT) and pulsed electrical stimulation to vagus nerve(s) |
US20050209654A1 (en) | 2002-05-09 | 2005-09-22 | Boveja Birinder R | Method and system for providing adjunct (add-on) therapy for depression, anxiety and obsessive-compulsive disorders by providing electrical pulses to vagus nerve(s) |
US20060079936A1 (en) | 2003-05-11 | 2006-04-13 | Boveja Birinder R | Method and system for altering regional cerebral blood flow (rCBF) by providing complex and/or rectangular electrical pulses to vagus nerve(s), to provide therapy for depression and other medical disorders |
WO2004110550A2 (en) | 2003-06-13 | 2004-12-23 | Biocontrol Medical Ltd. | Vagal stimulation for anti-embolic therapy |
US20060116739A1 (en) | 2002-05-23 | 2006-06-01 | Nir Betser | Electrode assembly for nerve control |
US8036745B2 (en) | 2004-06-10 | 2011-10-11 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic pacing therapy during and following a medical procedure, clinical trauma or pathology |
US7321793B2 (en) | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
US7277761B2 (en) | 2002-06-12 | 2007-10-02 | Pacesetter, Inc. | Vagal stimulation for improving cardiac function in heart failure or CHF patients |
US20040015202A1 (en) * | 2002-06-14 | 2004-01-22 | Chandler Gilbert S. | Combination epidural infusion/stimulation method and system |
US7203548B2 (en) | 2002-06-20 | 2007-04-10 | Advanced Bionics Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US20040015205A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators with programmable multielectrode configuration and uses thereof |
US7292890B2 (en) | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
KR100553516B1 (en) | 2002-06-24 | 2006-02-20 | 정종필 | Apparatus for inducing alpha -wave by electrical stimulation |
US20040049121A1 (en) * | 2002-09-06 | 2004-03-11 | Uri Yaron | Positioning system for neurological procedures in the brain |
US7209790B2 (en) * | 2002-09-30 | 2007-04-24 | Medtronic, Inc. | Multi-mode programmer for medical device communication |
EP1558130A4 (en) | 2002-10-15 | 2009-01-28 | Medtronic Inc | Screening techniques for management of a nervous system disorder |
EP1629341A4 (en) | 2002-10-15 | 2008-10-15 | Medtronic Inc | Multi-modal operation of a medical device system |
EP1558131A4 (en) | 2002-10-15 | 2008-05-28 | Medtronic Inc | Timed delay for redelivery of treatment therapy for a medical device system |
US20040138518A1 (en) | 2002-10-15 | 2004-07-15 | Medtronic, Inc. | Medical device system with relaying module for treatment of nervous system disorders |
WO2004037204A2 (en) | 2002-10-25 | 2004-05-06 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
US20030229380A1 (en) | 2002-10-31 | 2003-12-11 | Adams John M. | Heart failure therapy device and method |
US7305265B2 (en) | 2002-11-25 | 2007-12-04 | Terumo Kabushiki Kaisha | Heart treatment equipment for treating heart failure |
EP1426078A1 (en) | 2002-12-04 | 2004-06-09 | Terumo Kabushiki Kaisha | Heart treatment equipment for preventing fatal arrhythmia |
ES2293086T3 (en) * | 2002-12-06 | 2008-03-16 | The Feinstein Institute For Medical Research | INFLAMMATION INHIBITION USING COLINERGIC AGONISTS FROM UNION TO ALFA RECEIVER 7. |
US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
US20040111139A1 (en) | 2002-12-10 | 2004-06-10 | Mccreery Douglas B. | Apparatus and methods for differential stimulation of nerve fibers |
TR200202651A2 (en) | 2002-12-12 | 2004-07-21 | Met�N�Tulgar | the vücutádışındanádirekátedaviásinyaliátransferliáábeyinápil |
JP2004201901A (en) | 2002-12-25 | 2004-07-22 | Yoshimi Kurokawa | Stomach electrostimulator |
WO2004064918A1 (en) | 2003-01-14 | 2004-08-05 | Department Of Veterans Affairs, Office Of General Counsel | Cervical wagal stimulation induced weight loss |
WO2004064729A2 (en) | 2003-01-15 | 2004-08-05 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Treatments for snoring using injectable neuromuscular stimulators |
US20050143781A1 (en) | 2003-01-31 | 2005-06-30 | Rafael Carbunaru | Methods and systems for patient adjustment of parameters for an implanted stimulator |
US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
US7167750B2 (en) | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
CA2515368A1 (en) | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
US7269455B2 (en) | 2003-02-26 | 2007-09-11 | Pineda Jaime A | Method and system for predicting and preventing seizures |
US7783358B2 (en) | 2003-03-14 | 2010-08-24 | Endovx, Inc. | Methods and apparatus for treatment of obesity with an ultrasound device movable in two or three axes |
US20060015151A1 (en) * | 2003-03-14 | 2006-01-19 | Aldrich William N | Method of using endoscopic truncal vagoscopy with gastric bypass, gastric banding and other procedures |
US7430449B2 (en) | 2003-03-14 | 2008-09-30 | Endovx, Inc. | Methods and apparatus for testing disruption of a vagal nerve |
US6814418B2 (en) | 2003-03-14 | 2004-11-09 | D'orso Ronald | Locker organizer |
JP4252830B2 (en) * | 2003-03-24 | 2009-04-08 | テルモ株式会社 | Heart treatment equipment |
US7155279B2 (en) | 2003-03-28 | 2006-12-26 | Advanced Bionics Corporation | Treatment of movement disorders with drug therapy |
US7228167B2 (en) | 2003-04-10 | 2007-06-05 | Mayo Foundation For Medical Education | Method and apparatus for detecting vagus nerve stimulation |
US7706871B2 (en) | 2003-05-06 | 2010-04-27 | Nellcor Puritan Bennett Llc | System and method of prediction of response to neurological treatment using the electroencephalogram |
JP2007515200A (en) * | 2003-05-06 | 2007-06-14 | アスペクト メディカル システムズ,インク. | Evaluation system and evaluation method for therapeutic effectiveness of neuropathy using electroencephalogram |
DE10320863B3 (en) | 2003-05-09 | 2004-11-11 | Siemens Audiologische Technik Gmbh | Attaching a hearing aid or earmold in the ear |
US20050187590A1 (en) | 2003-05-11 | 2005-08-25 | Boveja Birinder R. | Method and system for providing therapy for autism by providing electrical pulses to the vagus nerve(s) |
US20060074450A1 (en) | 2003-05-11 | 2006-04-06 | Boveja Birinder R | System for providing electrical pulses to nerve and/or muscle using an implanted stimulator |
US20050197678A1 (en) | 2003-05-11 | 2005-09-08 | Boveja Birinder R. | Method and system for providing therapy for Alzheimer's disease and dementia by providing electrical pulses to vagus nerve(s) |
US7444184B2 (en) | 2003-05-11 | 2008-10-28 | Neuro And Cardial Technologies, Llc | Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s) |
US20060064137A1 (en) * | 2003-05-16 | 2006-03-23 | Stone Robert T | Method and system to control respiration by means of simulated action potential signals |
AU2004240663A1 (en) | 2003-05-16 | 2004-12-02 | Neurosignal Technologies, Inc. | Respiratory control by means of neuro-electrical coded signals |
US20060287679A1 (en) | 2003-05-16 | 2006-12-21 | Stone Robert T | Method and system to control respiration by means of confounding neuro-electrical signals |
US20060173508A1 (en) | 2003-05-16 | 2006-08-03 | Stone Robert T | Method and system for treatment of eating disorders by means of neuro-electrical coded signals |
US20060111755A1 (en) | 2003-05-16 | 2006-05-25 | Stone Robert T | Method and system to control respiration by means of neuro-electrical coded signals |
US7742818B2 (en) | 2003-05-19 | 2010-06-22 | Medtronic, Inc. | Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof |
US7620454B2 (en) | 2003-05-19 | 2009-11-17 | Medtronic, Inc. | Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof |
JP4213522B2 (en) | 2003-05-30 | 2009-01-21 | テルモ株式会社 | Heart treatment equipment |
US7738952B2 (en) | 2003-06-09 | 2010-06-15 | Palo Alto Investors | Treatment of conditions through modulation of the autonomic nervous system |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
EP1648558A4 (en) * | 2003-06-13 | 2015-05-27 | Biocontrol Medical B C M Ltd | Applications of vagal stimulation |
DE10328816A1 (en) | 2003-06-21 | 2005-01-05 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Implantable stimulation electrode with a coating to increase tissue compatibility |
JP2007530417A (en) | 2003-07-01 | 2007-11-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Composition for manipulating the longevity and stress response of cells and organisms |
WO2005007120A2 (en) | 2003-07-18 | 2005-01-27 | The Johns Hopkins University | System and method for treating nausea and vomiting by vagus nerve stimulation |
US7174218B1 (en) * | 2003-08-12 | 2007-02-06 | Advanced Bionics Corporation | Lead extension system for use with a microstimulator |
JP4439215B2 (en) | 2003-08-26 | 2010-03-24 | テルモ株式会社 | Heart treatment equipment |
US7263405B2 (en) * | 2003-08-27 | 2007-08-28 | Neuro And Cardiac Technologies Llc | System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities |
US7797058B2 (en) | 2004-08-04 | 2010-09-14 | Ndi Medical, Llc | Devices, systems, and methods employing a molded nerve cuff electrode |
US20050070974A1 (en) * | 2003-09-29 | 2005-03-31 | Knudson Mark B. | Obesity and eating disorder stimulation treatment with neural block |
US20050070970A1 (en) * | 2003-09-29 | 2005-03-31 | Knudson Mark B. | Movement disorder stimulation with neural block |
US20050075702A1 (en) | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
US7418292B2 (en) | 2003-10-01 | 2008-08-26 | Medtronic, Inc. | Device and method for attenuating an immune response |
US20050153885A1 (en) | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
US7062320B2 (en) | 2003-10-14 | 2006-06-13 | Ehlinger Jr Philip Charles | Device for the treatment of hiccups |
US20050095246A1 (en) | 2003-10-24 | 2005-05-05 | Medtronic, Inc. | Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators |
DE20316509U1 (en) | 2003-10-27 | 2004-03-11 | Lukl, Alfred | Ear acupressure and massage unit covers whole ear and applies sprung pins from commercial massage unit |
US20050131467A1 (en) | 2003-11-02 | 2005-06-16 | Boveja Birinder R. | Method and apparatus for electrical stimulation therapy for at least one of atrial fibrillation, congestive heart failure, inappropriate sinus tachycardia, and refractory hypertension |
CA2536242A1 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
US20050137645A1 (en) | 2003-12-05 | 2005-06-23 | Juha Voipio | Novel method for the adjustment of human and animal vagus nerve stimulation |
US7769461B2 (en) | 2003-12-19 | 2010-08-03 | Boston Scientific Neuromodulation Corporation | Skull-mounted electrical stimulation system and method for treating patients |
US7486991B2 (en) | 2003-12-24 | 2009-02-03 | Cardiac Pacemakers, Inc. | Baroreflex modulation to gradually decrease blood pressure |
US20050149129A1 (en) | 2003-12-24 | 2005-07-07 | Imad Libbus | Baropacing and cardiac pacing to control output |
US7460906B2 (en) | 2003-12-24 | 2008-12-02 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
US7422555B2 (en) * | 2003-12-30 | 2008-09-09 | Jacob Zabara | Systems and methods for therapeutically treating neuro-psychiatric disorders and other illnesses |
US8147561B2 (en) | 2004-02-26 | 2012-04-03 | Endosphere, Inc. | Methods and devices to curb appetite and/or reduce food intake |
WO2005089646A1 (en) | 2004-03-16 | 2005-09-29 | Medtronic, Inc. | Sensitivity analysis for selecting therapy parameter sets |
US7255675B2 (en) | 2004-03-23 | 2007-08-14 | Michael Gertner | Devices and methods to treat a patient |
US20160250097A9 (en) | 2004-03-25 | 2016-09-01 | The Feinstein Institute For Medical Research | Treatment of inflammation by non-invasive stimulation |
WO2006007048A2 (en) | 2004-05-04 | 2006-01-19 | The Cleveland Clinic Foundation | Methods of treating medical conditions by neuromodulation of the sympathetic nervous system |
US20060111644A1 (en) | 2004-05-27 | 2006-05-25 | Children's Medical Center Corporation | Patient-specific seizure onset detection system |
WO2006001982A2 (en) | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
US7565197B2 (en) | 2004-06-18 | 2009-07-21 | Medtronic, Inc. | Conditional requirements for remote medical device programming |
US7664551B2 (en) * | 2004-07-07 | 2010-02-16 | Medtronic Transneuronix, Inc. | Treatment of the autonomic nervous system |
US7711432B2 (en) | 2004-07-26 | 2010-05-04 | Advanced Neuromodulation Systems, Inc. | Stimulation system and method for treating a neurological disorder |
US7751891B2 (en) | 2004-07-28 | 2010-07-06 | Cyberonics, Inc. | Power supply monitoring for an implantable device |
US7204815B2 (en) | 2004-08-11 | 2007-04-17 | Georgia K. Connor | Mastoid ear cuff and system |
US8452407B2 (en) * | 2004-08-16 | 2013-05-28 | Boston Scientific Neuromodulation Corporation | Methods for treating gastrointestinal disorders |
US20050154425A1 (en) | 2004-08-19 | 2005-07-14 | Boveja Birinder R. | Method and system to provide therapy for neuropsychiatric disorders and cognitive impairments using gradient magnetic pulses to the brain and pulsed electrical stimulation to vagus nerve(s) |
US7580753B2 (en) * | 2004-09-08 | 2009-08-25 | Spinal Modulation, Inc. | Method and system for stimulating a dorsal root ganglion |
WO2006045054A2 (en) | 2004-10-18 | 2006-04-27 | E-Soc | Device for neuromusclar, peripheral body stimulation and electrical stimulation (es) for wound healing using rf energy harvesting |
WO2006047264A1 (en) | 2004-10-21 | 2006-05-04 | Advanced Neuromodulation Systems, Inc. | Peripheral nerve stimulation to treat auditory dysfunction |
US7672733B2 (en) | 2004-10-29 | 2010-03-02 | Medtronic, Inc. | Methods and apparatus for sensing cardiac activity via neurological stimulation therapy system or medical electrical lead |
US7818342B2 (en) | 2004-11-12 | 2010-10-19 | Sap Ag | Tracking usage of data elements in electronic business communications |
US8332047B2 (en) | 2004-11-18 | 2012-12-11 | Cardiac Pacemakers, Inc. | System and method for closed-loop neural stimulation |
US9089691B2 (en) | 2004-12-07 | 2015-07-28 | Cardiac Pacemakers, Inc. | Stimulator for auricular branch of vagus nerve |
US7366571B2 (en) | 2004-12-10 | 2008-04-29 | Cyberonics, Inc. | Neurostimulator with activation based on changes in body temperature |
US20060161217A1 (en) | 2004-12-21 | 2006-07-20 | Jaax Kristen N | Methods and systems for treating obesity |
AU2005323463B2 (en) | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US8825166B2 (en) | 2005-01-21 | 2014-09-02 | John Sasha John | Multiple-symptom medical treatment with roving-based neurostimulation |
US8788044B2 (en) | 2005-01-21 | 2014-07-22 | Michael Sasha John | Systems and methods for tissue stimulation in medical treatment |
US8609082B2 (en) | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
DE102005003735B4 (en) | 2005-01-26 | 2008-04-03 | Cerbomed Gmbh | Device for transcutaneous stimulation of a nerve of the human body |
US8600521B2 (en) | 2005-01-27 | 2013-12-03 | Cyberonics, Inc. | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity |
US7561918B2 (en) | 2005-01-28 | 2009-07-14 | Cyberonics, Inc. | Autocapture in a neurostimulator |
US20060173493A1 (en) | 2005-01-28 | 2006-08-03 | Cyberonics, Inc. | Multi-phasic signal for stimulation by an implantable device |
WO2006085065A2 (en) * | 2005-02-08 | 2006-08-17 | Janssen Pharmaceutica N.V. | Vagal afferent neurons as targets for treatment |
US8185199B2 (en) | 2005-02-10 | 2012-05-22 | Zoll Medical Corporation | Monitoring physiological signals during external electrical stimulation |
US7548780B2 (en) | 2005-02-22 | 2009-06-16 | Cardiac Pacemakers, Inc. | Cell therapy and neural stimulation for cardiac repair |
US20060200219A1 (en) | 2005-03-01 | 2006-09-07 | Ndi Medical, Llc | Systems and methods for differentiating and/or identifying tissue regions innervated by targeted nerves for diagnostic and/or therapeutic purposes |
US8700163B2 (en) | 2005-03-04 | 2014-04-15 | Cyberonics, Inc. | Cranial nerve stimulation for treatment of substance addiction |
US7613511B2 (en) | 2005-03-09 | 2009-11-03 | Cardiac Pacemakers, Inc. | Implantable vagal stimulator for treating cardiac ischemia |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
WO2011028763A2 (en) * | 2009-09-01 | 2011-03-10 | Setpoint Medical Corporation | Prescription pad for treatment of inflammatory disorders |
CN103619405B (en) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | The individual pulse being used for the treatment of the cholinergic anti-inflammatory pathway of chronic inflammatory disease activates |
-
2005
- 2005-03-24 JP JP2007505209A patent/JP2007530586A/en active Pending
- 2005-03-24 AU AU2005225458A patent/AU2005225458B2/en active Active
- 2005-03-24 WO PCT/US2005/009954 patent/WO2005092308A2/en active Application Filing
- 2005-03-24 CA CA002560756A patent/CA2560756A1/en not_active Abandoned
- 2005-03-24 EP EP05755668A patent/EP1734941A2/en not_active Withdrawn
- 2005-03-24 US US11/088,683 patent/US8729129B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2005092308A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005092308A2 (en) | 2005-10-06 |
AU2005225458B2 (en) | 2008-12-04 |
US8729129B2 (en) | 2014-05-20 |
CA2560756A1 (en) | 2005-10-06 |
US20050282906A1 (en) | 2005-12-22 |
JP2007530586A (en) | 2007-11-01 |
WO2005092308A3 (en) | 2005-12-01 |
AU2005225458A1 (en) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005225458B2 (en) | Neural tourniquet | |
US20210251848A1 (en) | Treatment of bleeding by non-invasive stimulation | |
Taylor | Agents acting at the neuromuscular junction and autonomic ganglia | |
AU2003298939C1 (en) | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists | |
TW201116534A (en) | Use of nicotinic acetylcholine receptor alpha 7 activators | |
JP2005525293A (en) | Analgesics and methods of use | |
JP2004511512A (en) | Combined use of an acetylcholinesterase inhibitor and a GABAA agonist for the treatment of cognitive impairment | |
JP2004527500A (en) | Nicotine receptor partial agonist, estrogen, selective estrogen modulator or combination of vitamin E and GABAA inverse agonist for the treatment of cognitive impairment | |
TW200819453A (en) | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism | |
JP2011511845A (en) | Combination of alpha 7 (α7) nicotinic agonist and antipsychotic | |
US20120322719A1 (en) | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways | |
JPH11501282A (en) | Epibatidine and its derivatives as cholinergic agonists and antagonists | |
US8642612B2 (en) | Nicotinic desensitizers and methods of selecting, testing, and using them | |
JP3542893B2 (en) | (N- (pyridinylmethyl) -heterocyclic) ylideneamine compounds as nicotine-like acetylcholine receptor binding agents | |
US20110112128A1 (en) | Method of treating ileus by pharmacological activation of cholinergic receptors | |
Poliacek et al. | Central administration of nicotine suppresses tracheobronchial cough in anesthetized cats | |
Hibbs et al. | Agents acting at the neuromuscular junction and autonomic ganglia | |
TWI759579B (en) | Sleep disorder treatment and prevention | |
JP2007506784A (en) | Cererythrin, its analogs and their use in the treatment of bipolar disorder and other cognitive disorders | |
TW202106302A (en) | Method for treating cough by using diaminopyrimidine compound | |
CN107531670B (en) | Diarylmethylidene piperidine derivatives and their use as opioid receptor agonists | |
US20210077478A1 (en) | Method of countering respiratory depression via activation of neuronal heteromeric nicotinic acetylcholine receptors | |
WO2006063010A2 (en) | Compounds and methods of use thereof | |
Nagelhout | Neuromuscular Blocking Agents, Monitoring | |
Sultatos et al. | Articles in PresS. Am J Physiol Endocrinol Metab (June 26, 2012). doi: 10.1152/ajpendo. 00622.2011 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061020 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070831 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080311 |